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Abstract
c-myc is a well-known proto-oncogene encoding a transcription factor that 
needs to be tightly regulated in order to preserve cell homeostasis. The Promyelocytic 
Leukaemia gene product PML plays an important role in cell growth and survival, and 
resides in discrete sub-nuclear structures called Nuclear Bodies (NB). PML is largely 
involved in gene regulation via recruitment of several transcription factors and co­
factors to the NB. In this report, I show that Myc partially localizes to the NB and 
physically interacts with PML, and I demonstrate that PML over-expression affects 
Myc-mediated transcription of a reporter gene. Comparative analysis of the expression 
of 40 Myc target genes and of Myc binding to their regulatory regions in wild type and 
PML knockout mouse embryo fibroblasts was performed. The data show that if PML 
is absent, although Myc binding to the DNA regulatory sequences is unchanged, the 
expression profile of several Myc target genes is altered. As deregulation of both 
activated and repressed Myc target genes occurs, I propose that PML influences Myc 
transcriptional activity through a mechanism that involves the control of Myc post- 
translational modifications.
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CHAPTER 1: Introduction
1.1-The myc family of proto-oncogenes
The c-myc gene was originally identified as the cellular homologue of v-myc, 
the oncogene captured by the avian MC29 myelocytomatosis transforming virus 
(Alitalo et al., 1983a; Alitalo et al., 1983b; Sheiness et al., 1978). c-myc belongs to 
the family of m yc  genes, which includes B-myc, L-myc, N-myc and s-myc 
(Ingvarsson et al., 1988; Legouy et al., 1987; Schwab et al., 1984; Sugiyama et al., 
1989). The structural and biochemical features of Myc proteins mark them as direct 
regulators of gene expression.
1.1.1-Myc is a  m em ber of the basic-H elix-loop-H elix-leucine Z ipper 
(bHLHZ) superfamily of transcription factors
The c-myc gene structure consists of three exons that encode for a polypeptide 
of 439 aa with two conserved regulatory motifs at the N terminus (Myc Box I and 
Myc Box 11), and a C-terminal basic-helix-loop-helix leucine zipper (bHLHZ) 
domain, in which the basic region (b) is required for specific DNA sequence 
recognition and binding, while the helix-loop-helix and the leucine zipper motifs 
(HLHZ) determine the specific dimer formation between Myc and its obligate partner 
Max, another bHLHZ protein, in order to bind a six-nucleotide E-Box sequence 
CACGTG, and activate transcription of several genes (Fig. 1.1 and 1.4) (Baudino and 
Cleveland, 2001; Luscher and Larsson, 1999).
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The presence of a conserved Myc-like bHLHZ domain is a hallmark of the 
transcription factors of this protein family. Apart from the canonical E-Box consensus 
sequence, Myc-Max can also bind many types of non-consensus E-Box elements, such 
as CATGTG, CACGTG, CATGCG, CACGCG, CAACGTG, and CACGAG 
(Blackwell et al., 1993). Statistically, the consensus and non-consensus E-boxes are 
distributed throughout the genome at a frequency of l/800bp, however, Myc seems to 
bind preferentially the E-Box sequences located in the vicinity of gene regulatory 
sequences, suggesting that Myc binding might be sensitive to unique structural 
features of gene promoters, like the presence of CpG islands (Fernandez et al., 2003). 
Myc-binding to the E-box targets is antagonized by Mad-1, Mxi-1, Mad-3, Mad-4 and 
Mnt bHLHZ proteins, which compete with Myc in binding with Max to the E-Box 
sequences, although providing transcriptional repression via an N-terminal mSin3 
corepressor-binding domain that recruits co-repressors and histone deacetylases 
(HDACs) (Grandori et al., 2000).
The Max bHLHZip Superfamily
activstion o f frmiscnptioit
itpiession of trajnsci ipticn
leucine
DNA
basic région
F ig l.l . Schematic representation of the Max Superfamily of 
transcription factors. All of the proteins indicated in yellow are 
obligate partners of Max in order to bind DNA and to either activate or 
repress transcription.
1.1.2-Myc-mediated transcriptional activation
Once bound to the target E-box sequences (Fig. 1.2), Myc can activate gene 
expression through multiple regulatory events. Particularly, Myc can activate 
transcription either via the recruitment of transcription co-factors such as histone 
acetyltransferases and of ATP-dependent chromatin remodelling complexes, or at the 
level of transcription initiation and elongation, via interaction with the RNA 
Polymerase II complex (Bouchard et al., 2001; Cheng et al., 1999; Bberhardy and 
Farnham, 2001; Frank et al., 2001; Xu et al., 2001). A head-to-tail pair of Myc-Max 
dimers may form a heterotetramer that is capable of bridging distant E-boxes, which 
contribute to gene regulation (Nair and Burley, 2003).
1.1.3-Myc-mediated transcriptional repression
On the other hand, Myc may also act as a repressor, as it lowers the 
expression levels of its target genes by direct interference either with the 
transcriptional machinery, or with the enhancers required to induce gene expression 
(Fig. 1.3). As a matter of fact, Myc binds the TATA-box binding protein TBP along 
an auxiliary pathway to control gene expression; moreover, several targets seem to be 
repressed by Myc through the initiator sequence (Inr), and others may undergo 
modification of expression on an ad hoc basis through the direct interaction of Myc 
with other transcriptional elements, like Spl, NF-Y, Miz-1, Smad, YY-1, AP2, and 
other proteins (Fig. 1.4) (Facchini and Penn, 1998; Feng et al., 2002; Cartel et al., 
2001 ; Izumi et al., 2001 ; Staller et al., 2001).
Mechanisms of Myc Transcriptional activation
a) Mvc Max
b) / V  \  Myc I Max)
c)
X /"
Myc IMax ;
target gene 
E-Box
Fig. 1.2. Mechanisms of Myc-mediated transcriptional activation:
a) Myc-Max dimer binds to an E-box sequence within the first intron.
b) Myc-Max dimer binds to an E-box sequence within the first exon.
c) Myc-Max dimer binds to an E-box sequence within the promoter region.
Mechanisms of Myc Transcriptional repression
a)
b)
Mvc I Max
target gene 
preinitiation complex (PIC) 
transcription factor
Fig. 1.3. Mechanisms of Myc-mediated transcriptional repression:
a) Myc-Max dimer binds to the PIC and blocks its transcriptional activity.
b) Myc-Max dimer binds to a transcription factor and impairs its activity.
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Fig.1.4. Myc structure, functional domains and sites of interaction. Myc box I
(MbI) is mainly involved with transcriptional activation, whereas Myc box 11 (Mbll) 
is indispensable for Myc-mediated repression.
Many of the interactions of Myc with its partners occur in the N-terminal or C- 
terminal domains.
1.1.4-Myc and chromatin remodelling
Besides its activity as a basic transcription factor, Myc is currently being 
investigated as modulator of the chromatin status. Indeed, several evidences have 
connected Myc with the major chromatin remodelling complexes, as elucidated by the 
physical interaction of Myc with both the SWI/SNF ATP-dependent remodelling 
complex, which uses energy to modify chromatin structure in a non-covalent manner, 
and the histone acetyl-transferase (HAT) core, a multiprotein complex that mobilizes 
nucleosomes by acétylation of the H3 and H4 histone tails (Frank et ah, 2003; Liu et 
ah, 2003). Finally, a clear involvement of Myc in DNA repair has been proposed 
(Chiang et ah, 2003; Partlin et ah, 2003).
1.1.5-Myc function in normal cells
Myc regulates diverse cellular processes integral to cell growth, survival and 
development. Due to its involvement in such important matters, Myc activity is tightly 
controlled by a precise and combined regulation of mRNA and protein expression 
levels, c-myc is an early serum-response gene, as its expression is induced by 
mitogenic signals provided by extra-cellular stimuli. Myc expression peaks in the early 
G1 phase, and returns to a basal level as cells enter the S phase (Henriksson and 
Luscher, 1996). Moreover, Myc protein half-life is extremely short, 15-20 minutes, 
and its rapid degradation occurs in a proteasome-dependent manner (Salghetti et ah, 
1999). Myc expression is a prerequisite for cellular proliferation, since rodent cells 
where both c-myc alleles are depleted (c-myc-/-) show an extremely increased
doubling time (Mateyak et al., 1997), and c-myc-/- mouse embryos die at embryonic 
day 9.5-10.5 (Davis et al., 1993).
1.1.6-Myc and Cancer
Myc misregulation leads to cancer, and its transforming potential can be 
elicited by both genetic and epigenetic events, such as chromosomal translocation or 
deregulated expression caused by constitutive activation of growth factor receptors, 
respectively (Nesbit et ah, 1999). Myc over-expression determines uncontrolled cell 
proliferation but also increased apoptotic cell death, which provides a mechanism that 
counterbalances myc oncogenic potential. The transformation of a normal cell into a 
cancer cell requires that sustained Myc-induced proliferation and defective Myc- 
induced apoptosis simultaneously occur.
In addition, Myc deregulated expression strongly induces genomic instability, 
mainly by positive regulation of genes that promote cell growth and proliferation, and 
by negative regulation of genes that induce cytostatic effects and DNA surveillance 
(Chiang et ah, 2003; Grandori et ah, 2003; Seoane et ah, 2002).
1.1.7-Myc regulatory pathways
Due to the multiple regulatory mechanisms it takes part in, it has been 
suggested that Myc might be induced to discriminate the choice of the partner by post- 
translational modifications. Myc protein is subjected to several modifications, namely 
phosphorylation, glycosylation, ubiquitination, and, most recently described,
acétylation (Kamemura et al., 2002; Salghetti et al., 1999; Sears et al., 2000; Vervoorts 
et al., 2003). These modifications seem to play antagonistic roles on the Myc protein 
fate and function. As an example, glycosylation occurs at Threonin 58, which is also a 
well-known target of phosphorylation strictly connected with Myc activation and 
degradation. Likewise, ubiquitination of Myc, which preferentially occurs at the N 
terminus, seems to be antagonized by acétylation (Vervoorts et ah, 2003). It has been 
recently shown that ubiquitination of transcription factors is commonly required for 
their functional activation (Salghetti et ah, 2001), therefore it is possible to 
hypothesize that the regulation of Myc ubiquitination levels is important not only to 
induce its degradation process but also to modulate its transcriptional properties.
1.2-The PML gene
The Promyelocytic Leukaemia (PML) gene was originally identified in patients 
affected by Acute Promyelocytic Leukaemia (APL), where it is fused to the retinoic 
acid receptor a  (R A R a) gene, due to t(15;17) chromosomal translocation that 
generates the chimeric proteins PML/RARa and RARa/PML (Fig. 1.5) (de The et ah, 
1991; Goddard et ah, 1991). This fusion event accounts for 99% of Acute 
Promyelocytic Leukaemia (APL) cases (Ruggero et ah, 2000).
The chimeric protein PML/RARa is insensitive to physiological retinoic acid 
concentration, resulting in the block of myeloid haematopoietic cell terminal 
differentiation and in their uncontrolled proliferation (Lin et ah, 1999).
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1.2.1-PML belongs to the TRIM protein family
PML is a nuclear phosphoprotein belonging to the TRIM protein family 
(Reymond et ah, 2001), with a N-terminal RING finger domain (R) followed by two 
additional zinc fingers named respectively B-Boxl and B-Box2 (BB), a coiled-coil 
region (CC) and a C-terminus that shows different aminoacidic sequences due to 
multiple alternative splicing variants (Fig. 1.6) (Jensen et ah, 2001). Genes of this 
family are implicated in a variety of processes, such as development and cell growth, 
and are involved in several human diseases. PYRIN/MARENOSTRIN, MIDI and 
MUL are mutated in Familial Mediterranean Fever, X-linked Opitz/GBBB syndrome, 
and Mulibrey nanism, respectively ( The International FMF, 1997a; The French FMF , 
1997b; A vela et ah, 2000; Quaderi et ah, 1997), whereas PML, RFP and T ifl acquire 
oncogenic activity when fused to RARa, RET or B-raf, respectively (Grignani et ah, 
1994; Le Douarin et ah, 1995; Ruggero et ah, 2000; Takahashi et ah, 1988).
11
q22 (PML)
\
X
chioiiiosoiiie 15>
q l2 (Ri\Ra)
\
chrom osom e 17
Fig.1.5. 99% of Acute Promyelocytic Leukaemia are due to a balanced translocation 
between chromosomes 15 and 17. This event occurs at the level of PML and RARa 
gene loci, and determines the formation of the two chimeric proteins PML/RAR a  
and RAR a/PML.
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PML
TRIpaiTitc M otif containing protein (TRIM)
/  \ /  \
1 \ /  \
(5' 1 1 T ) :  1
/
/ Z n y
C-terminal 
domain: 
several splicing  
isoforms
Fig.1.6. PML belongs to the TRIM protein family. The signature of this family is 
the Tripartite Motif, which consists of a RING, a B-boxl, a B-box 2 and a coiled- 
coil domain at the N-terminus of the protein. In each protein, the single domains, 
when present, always respect this definite order within the aminoacidic sequence.
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1.2.2-PML and the Nuclear Bodies
PML can homo-multimerize, and localizes within discrete nuclear structures 
called nuclear bodies (NB), PML oncogenic domains (PODs) or nuclear domain 10 
(NDIO) (Fig. 1.7). Cells typically contain 5-30 NB of 0.2-1 pim, even if the number and 
size may vary according to the cell cycle phase, the external signals and the cell type 
(Doucas and Evans, 1996; Everett et al., 1999; Koken et al., 1995). PML protein levels 
and NB number and size are increased in inflammatory tissues and as a cellular 
response to interferon, and NB disruption is an early event caused by several viral 
infections (Gongora et al., 1997; Guldner et al., 1992; Terris et al., 1995). PML 
localization to the NB is a prerequisite for the formation and maintenance of their 
macromolecular structure (Ishov et ah, 1999; Zhong et ah, 2000). In APL blasts, 
PML/RARa protein targets and délocalisés PML, causing the destruction of the NB 
into micro-speckled structures; treatment of APL patients with all-trans retinoic acid 
induces dramatic differentiation of the leukemic blasts with rapid degradation of 
PML/RARa and recovery of normal NB (Melnick and Licht, 1999).
1.2.3-The functional role of the NB
The NB act like nuclear compartments where several proteins committed to 
different functions stably or transiently localize (Fig. 1.7). Moreover, they are sites of 
intense protein post-translational modification events, like acétylation, sumoylation, 
ubiquitination and phosphorylation (D'Orazi et ah, 2002; Doucas et ah, 1999; Everett 
et ah, 1997; Hofmann et ah, 2002; Muller et ah, 1998).
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The plethora of biochemical events of cellular and viral origin that associate 
with the NB topology and composition support the view of the NB as integrators of 
multiple extra cellular stimuli. Indeed, PML is involved in multiple different 
biological functions, like cell growth, proliferation, differentiation, and apoptosis, and 
the functional significance of PML employment has been investigated in depth during 
the last few years. Interestingly, several lines of evidence have shown that PML and 
the NB intervene in the regulation of gene expression and in DNA stability. PML is 
involved in both the activation and repression of several target genes, as it physically 
interacts with several transcription factors, like Spl, p53, pRB and c-Jun (Alcalay et 
al., 1998; Best et al., 2002; Fogal et al., 2000; Vallian et al., 1998a; Vallian et al., 
1998b), and it influences gene expression by preferential recruitment of HATs, like 
CBP and p300 (Doucas et al., 1999; LaMorte et al., 1998), or HDACs and co­
repressors (Khan et al., 2001; Langley et al., 2002; Wu et al., 2001) at the NB. 
Moreover, PML interacts with several proteins that control DNA genomic stability and 
repair (Naka et al., 2002; Zhong et al., 1999) and with the proteasome (Lallemand- 
Breitenbach et ah, 2001), even if the functional significance of the interaction with the 
degradation machinery is still obscure.
1.2.4-PML acts like a tumour suppressor
There is growing evidence that PML acts like a tumour suppressor. In addition 
to the ability to preserve genomic stability, PML over-expression inhibits cell growth 
and proliferation, suppresses lymphomagenesis in mice (Wang et ah, 1998a), and 
induces apoptosis (Guo et ah, 2000; Koken et ah, 1995; Liu et ah, 1995; Quignon et
15
al., 1998; Wang et al., 1998b). Moreover, PML belongs to the pathway that leads cells 
to oncogenic Ras-dependent and independent senescence. Upon cell-entry into 
senescence, both PML levels and NB number and size increase (Ferbeyre et ah, 2000; 
Jiang and Ringertz, 1997; Pearson et ah, 2000), and PML may elicit induction of 
senescence by enhancing p53 and pRB activity (De Stanchina et ah, 2004; Fang et ah, 
2002; Gottifredi and Prives, 2001) and by promoting both transcriptional activation 
and repression via modulation of several transcription factors activity.
16
The functional role of the NB
HDAC. kinases
coi’epressoi's/piV nj-^ ^
^  _ IE
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subuiiits
oteasome)
H A T
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Fig.1.4. PML localizes to the Nuclear Bodies (NB), and interacts with several 
proteins. Due to the diversity of the roles played by the proteins that are recruited 
to the NB, PML is involved in several cellular processes, such as cell growth, 
proliferation and apoptosis, acting either as a co-activator or as a co-repressor.
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1.3-Myc and PML play antagonistic roles in several cell pathways
Several lines of evidence account for the involvement of Myc and PML in 
common cellular regulatory events, where they seem to play antagonistic roles.
1.3.1-Transformation assay
One of the most classical approaches to classify a novel gene as a potential 
oncogene is to investigate its ability to transform a primary culture of Rat Embryo 
Fibroblasts, when co-transfected with the constitutively activated oncogenic Ha-Ras. 
Following co-transfection with Ras, Myc induces cell transformation, which defines it 
as a proto-oncogene (Lee et al., 1985). Conversely, using the same functional 
approach, PML suppresses growth of Rat Embryo Fibroblasts transformed by co­
expression of the Ha-Ras oncogene and c-Myc, therefore showing tumour suppression 
properties (Mu et al., 1994).
1.3.2-Cellular proliferation
Other indications arise from the recent insights on the Ras pathway. As 
mentioned above, PML is up-regulated by Ras, and leads to premature cell senescence 
through the induction of the p ll^^^ ' gene, a cell cycle inhibitor, and the functional 
activation of p53 tumour suppressor (Fogal et al., 2000; Pearson et al., 2000). As a 
proof, PML-/- Mouse Embryo Fibroblasts (MEFs) show complete loss of Ras induced 
senescence and increased resistance to apoptosis (Guo et al., 2000; Wang et al., 
1998a). Moreover, in human cells, PML contributes to Ras mediated cell cycle arrest
18
by engaging also the pRB suppression pathways via up-regulation of the intracellular 
levels of the cell cycle inhibitor Conversely, Myc antagonizes p l6  and p21
cytostatic effect and pRB- and p53-mediated tumour suppression pathways (Ferbeyre 
et al., 2000; Obaya et al., 1999).
1.3.3-Cell-cycIe progression
Myc and PML oppositely influence the cell cycle progression. Both genes 
expression profile show a peak in the G1 phase (Chang et al., 1995; Rabbitts et al., 
1985); however, while Myc over-expression induces S-phase entry, an increased 
amount of PML results in a delayed cell exit from G l. Consistently, the extremely 
delayed G l phase observed in c-myc -/- MEFs is also found in cell lines over­
expressing PML (Mu et al., 1997), whereas PML-/- MEFs and cells over-expressing 
Myc undergo opposite effect (Grandori et al., 2000; Wang et al., 1998a).
1.3.4-Chromatin remodelling
The role that PML plays in chromatin remodelling mainly relies on PML- 
dependent recruitment of both histone acétylation and deacetylation complexes to the 
NB (Ruggero et al., 2000; Wu et al., 2001). Given the emerging involvement of Myc 
in chromatin remodelling (Amati et al., 2001), it is possible to hypothesize that the 
reciprocal influence of Myc and PML in this mechanism may regulate gene 
transcription within defined chromatin regions.
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1.3.5-Gene expression
Evidence of the interaction of PML with the Myc network comes from the 
involvement of PML in M adl mediated repression (Khan et al., 2001). PML 
physically binds HDACl, and directly assists M adl to target genes repression (Wu et 
al., 2001). From a general point of view, it is known that Myc and Mad protein levels 
determine cell fate (Henriksson and Luscher, 1996; Queva et al., 1998). For example, 
the onset of the differentiation pathway of haematopoietic precursors is determined by 
the switching from MyciMax to Mad 1/Max binding to target genes (Grandori et al., 
2000). It was recently proven that this switching correlates with the histone acétylation 
status of the telomerase reverse transcriptase promoter in the promyelocytic leukaemia 
human cell line HL60 (Xu et al., 2001). The mad genes share with Myc the majority of 
their target genes (Luscher, 2001; Nikiforov et al., 2003); this implies that, from a 
more general perspective, PML may antagonize Myc activity at least in an indirect 
way, for example by inducing histone deacetylation, which could promote nucleosome 
assembly and render gene promoters inaccessible to Myc.
Accordingly, it was recently described the discovery of a novel trans­
repression pathway of Myc via the recruitment of a Trichostatin-A (TSA) sensitive 
transcriptional co-repressor complex to Myc through interaction with the adaptor 
protein MM-1 (Satou et al., 2001). TSA is a drug that inhibits the activity of HDAC 
protein family, and the discovery that Myc-mediated transcriptional activation 
dramatically increases after treatment of cells with TSA opens new questions on the 
mechanism by which Myc mediates transcriptional regulation. In view of the fact that 
the HDAC-mediated repression activity is associated to Myc via the TRIM protein
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T IF lp , which is indirectly recruited to Myc via physical interaction of MM-1 with 
both proteins, it would be interesting to investigate if PML could also directly or 
indirectly recruit HDAC complexes to Myc as well.
1.3.6-PML interacts with several Myc transcription partners
In parallel to this, other insights suggest that PML might antagonize Myc 
function by influencing Myc transcriptional activity. In fact, as the NB have been 
proposed to serve as depots for the deployment and decommission of various proteins, 
PML could regulate the availability of specific transcription co-factors that cooperate 
with c-Myc.
One example comes from the interferon pathway. As mentioned above, PML 
expression is up-regulated by interferons (IFNs) (Heuser et al., 1998) and correlates 
with IFN-induced antiviral and antiproliferative effects (Ruggero et al., 2000; Turelli 
et al., 2001). Of note, c-myc shares many target genes with IFN-y, and c-myc over­
expression results in a global deregulation of multiple IFN-responsive genes (Nesbit et 
al., 2000). The regulatory region of many Myc target genes contain Spl-binding sites 
that contribute to basal expression, so that genes might undergo cooperative regulation 
by Myc and the transcription factor Spl (Boyd and Famham, 1997). Spl is known to 
interact with PML (Vallian et al., 1998a), and therefore could be actively sequestered 
in the PML bodies.
In addition, PML interacts with cyclin T l , a subunit of the positive 
transcription elongation factor b (P-TEFb), both at the NB and associated to a target 
promoter, suggesting that PML could regulate transcription by modulating the
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availability of cyclin T l and through a direct interaction with the transcription 
machinery (Marcello et al., 2003). Noteworthy, it was recently shown that Myc 
activates transcription of the CAD gene by recruitment of the P-TEFb to its promoter 
(Eberhardy and Farnham, 2002; Kanazawa et al., 2003), and this enrollment is 
mediated by Myc physical interaction with cyclin T l. Since Myc and PML bind two 
distinct cyclin T l regions, cyclin T l could simultaneously interact with Myc and 
PML, not only at the NB, but also at Myc target genes regulatory regions.
1.3.7-Myc is a target of multiple post-translational modification pathways 
that occur within the NB.
Finally, the influence of PML on Myc activity could occur at the level of Myc 
post-translational modifications. As mentioned above, it was recently proposed that 
ubiquitination of Myc might compete with CBP-mediated acétylation (Vervoorts et al., 
2003). In particular, Myc ubiquitination enhances Myc transcriptional activity via 
recruitment of proteasome subunits (Kim et al., 2003; von der Lehr et al., 2003). 
Proteasome subunits directly participate in the activation of Myc target genes, having 
been found together with Myc on the promoter of the gene encoding for cyclin D2. 
Interestingly, PML interacts with the proteasome and recruits CBP at the NB as well, 
suggesting that it could be involved in the regulation of Myc post-translational status 
(Lallemand-Breitenbach et al., 2001).
1.4-Aim of the project
The aim of this project was to assess the involvement of PML in the Myc 
pathway. To this end, I focused in parallel on two main goals: the evaluation of PML
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physical interaction with Myc, and the analysis of the influence of PML on Myc target 
genes regulation.
The physical interaction between the two proteins was investigated by co­
localization and co-immunoprecipitation experiments, whereas the functional assay 
consisted of the evaluation of PML influence on Myc transcriptional activity. To this 
purpose, I selected several known or putative Myc direct target genes, and I performed 
a comparative analysis of Myc binding to their regulatory regions and of their 
expression levels in wt and PML knock out (-/-) Mouse Embryo Fibroblast (MEFs). In 
order to perform this comprehensive analysis, I split my efforts into two main parts:
1) Validation of Myc binding to target genes by chromatin immunoprécipitation 
(ChIP) in the two cell lines. This technique has been proven very powerful to study the 
activity of mammalian transcription factors (Boyd and Farnham, 1999). The specific 
immunoprécipitation of DNA/Myc cross-linked regulatory regions with a -M y c  
antibodies, from wt and PML^ synchronized MEFs at defined time points, spanning 
the whole G l phase, was performed in order to evaluate if a selected set of known 
Myc targets is differently occupied by the Myc:Max dimer in presence or absence of 
PML protein.
2) Analysis of the expression profile of the validated Myc target genes by Real 
Time quantitative PCR in the two synchronized cell types at the same time points, in 
order to reveal if a subset of Myc target genes is differentially expressed in absence of 
PML, and if this can be related to Myc binding to their regulatory regions.
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CHAPTER 2: Materials and Methods
2.1-Cloning of Myc and PML into constructs suitable for expression in eukaryotic 
cells
2.1.1-Production of insert and vector DNA fragments
The full-length of the murine c-Myc and human PML IV cDNA were cloned 
into pCMV-2-Flag (SIGMA) and pCDNA3-HA vectors, which are designed for 
protein expression in mammalian cells (Invitrogen).
To clone the two genes. Polymerase Chain Reaction (PCR) was performed using 
primers with restriction site-containing tails; particularly, the forward primer carries an 
EcoRI site upstream of the ATG start codon, which keeps the genes translationally in 
frame with the tag sequence, and an Xhol site downstream of the stop codon.
In order to generate the insert DNA, PCR was performed in final 50//1 samples, 
using lOOng of DNA template, 500nM forward and reverse primers, 5fi\ of I Ox Vent 
DNA Polymerase buffer, 0.2mM dNTPs, and 0.5/d (lU ) of the high fidelity Vent 
DNA Polymerase (New England Biolabs). The amplification reaction was carried out 
with as follows:
1. I min at 95°C
2. I min at 95°C
3. 30 sec at 56°C
4. 4 min at 75°C for PML amplification, 3 min at 75°C for Myc 
amplification (about I min/500bp of cDNA length).
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5. Steps 2 to 4 are repeated 30 times
6. 1 cycle: 10 min at 75°C
In order to check the efficiency of the PCR reaction, 5//1 of the samples were 
loaded on a 1% agarose gel, consisting of I % weight/volume (w/v) agarose and final 
0.2/ig/ml Ethidium Bromide diluted in TAE (40mM Tris-acetate, pH 7.5, 2mM 
EDTA), and checked under a UV lamp after electrophoretic run. Positive samples 
were subjected to protein extraction by adding I volume (Vol) of phenol/clorophorm, 
and centrifuging I min at I4,000rpm in a bench centrifuge at room temperature (RT). 
The upper phase was collected, and DNA was precipitated in 2.5Vol 100% ethanol 
and I/IOVol of 3M Sodium Acetate pH 4.8. After centrifuging 5min at I4,000rpm at 
RT, the pellet was washed with I00//1 of 70% ethanol, and let dry at RT.
2.1.2-DNA restriction
In order to restrict the fragment tails at the EcoRI and Xhol sites, DNA pellet 
was resuspended in 43//I of distilled water, 5pi\ of I Ox EcoRI buffer, which is 
compatible also with the Xhol restriction enzyme, were added, and the samples were 
incubated at 37°C for I hr with I//1 of EcoRI and Xhol 20,000U/ml restriction 
enzymes, in 50//1 final volume. All the restriction enzymes were from New England 
Biolabs. Then, the digestions were loaded on a 1% agarose gel, and the DNA bands 
that showed the expected size were cut from the gel with a razor blade, extracted from 
the gel using Qiaex II extraction kit (Qiagen) according to the m anufacturer’s 
protocol, and resuspended in 25/d of Ix TE buffer (lOmM Tris-Cl, pH 7.5, ImM 
EDTA).
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Extraction efficiency was determined by loading 5//1 on an agarose gel. 
Parallel to this, pCDNA3-HA and pCMV-2-FLAG were opened by digestion with 
EcoRI-XhoI and EcoRI-Sall restriction enzymes, respectively, purified by gel 
extraction as reported above (DNA digestion with Sail and Xhol enzymes provide 
compatible, not re-cleavable, ends), and quantified on gel.
2.1.3-DNA ligation
After diluting insert and vector DNA at the final concentration of about 
100ng///l, the ligation reactions were carried out in final 10/d sample volume, adding 
1/d lOx ligation buffer, 1/d vector DNA, 2.5-5/d insert DNA, and 0.5//1 T4 DNA 
Ligase (New England Biolabs), and incubating Ihr at RT. 5pi\ of each reaction was 
used for transformation of bacterial cells.
2.1.4-DNA transformation
In order to insert the constructs into the bacterial host cells, 50//1 of chemical 
competent DH5a E. Coli cells, with an efficiency of at least 10  ^ colonies//<g DNA///1 
cells, were incubated for 20 min on ice with 5//1 of ligation samples, followed by 2 min 
thermal shock at 42°C, then I ml Luria Broth (LB: I % bactotryptone, I % NaCl and 
0.5 % Bacto-yeast extract) was added, and cells were incubated 45 min at 37°C in a 
water bath, centrifuged 2 min at 5,000rpm, resuspended in 20//1 LB and plated on 
100mm diameter B-agar Petri dishes containing lOO/ig/mg ampicillin, which allows the
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selection of the transformed colonies, as the used vectors confer resistance to this 
antibiotic.
2.1.5-Clonal selection
Plates were incubated over night (o.n.) at 37°C, and then the grown colonies 
were picked and grown o.n. at 37°C in liquid LB medium. After plasmid DNA 
purification, the constructs were analysed by restriction digestion with EcoRI-XhoI 
enzymes, and the positive clones were subjected to direct sequence analysis by the 
sequencing core at TIGEM.
2.2-Purification of plasmid DNA and DNA quantification
Plasmid DNA preparations were performed using the Qiagen Midi or Mini 
preparation kits, according to the manufacturer’s instructions (Qiagen), which provided 
large and small amounts of purified DNA, respectively. DNA concentration was 
determined by spectrophotometer analysis at the fixed 260nm UV wavelength. DNA 
concentration is determined by the formula [C] = sA, where [C] =DNA concentration, 
A =absorbance, and 8 = double strand DNA molar extinction coefficient, which is 
50//g/ml (RNA = 40, single-strand DNA = 33).
2.3-Cell culture and synchronization
Mouse Embryo Fibroblasts (MEFs)(Wang et al., 1998a) were grown in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 20% Fetal Bovine 
Serum (FBS, Invitrogen), 50jaM  B-mercaptoethanol, lOOU/ml penicillin/streptomycin
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and 2mM Glutamine, and split 1:3 every three-four days. For ChIP and Real-time 
experiments, cells at passage 9 were used, and 80% confluent MEFs were 
synchronized by 72-hour-starvation in DMEM supplemented with 0.1% FBS, 50//M 
B-mercaptoethanol, lOOU/ml penicillin/streptomycin, and 2mM Glutamine, followed 
by re-addition of DMEM with 20% FBS and harvesting at the selected time points. 
Cos-7, HeLa, U20S, HEK 293, HepG2 and NIH-3T3 cell lines were grown in DMEM 
supplemented with 10% FBS (SIGMA), lOOU/ml penicillin/streptomycin, and 2mM 
Glutamine.
2.4-Transient transfection and transactivation assay
For these studies, I used murine c-Myc cloned into a pCMV-2-Flag vector and 
human PML isoform IV cloned into a pCDNA3-HA.
Plasmid DNA was purified with the Qiagen Midi Kit and used to transfect HeLa, Cos- 
7, HepG2, U20S, HEK 293 and NIH-3T3 cell lines with Polyfect (Qiagen) according 
to the manufacturer’s instructions. MEFs were transfected with Effectene (Qiagen). In
transactivation experiments, 1.2x10^ HeLa, HepG2, or HEK 293 cells/well were 
seeded in I2-well-plates and transfected with M4-tk-luc (carrying 4 E-box sequences 
in the promoter region) or tk-luc (kindly provided by B. Liischer). Luciferase activity 
was assayed 48hrs post-infection according to the manufacturer’s instructions 
(Promega). Transactivation assays were performed in triplicate and repeated at least 
three times.
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2.5-Antibodies
Rabbit polyclonal anti-Myc N-262 (Santa Cruz), rabbit polyclonal anti-PML 
H-238 (Santa Cruz), monoclonal anti-Flag M2 (SIGMA) and monoclonal anti-HA 
(Boerhinger) were used for immunoprécipitation; anti-Myc N-262 and anti-PML H- 
238 were utilized for Western blot analysis. For immunofluorescence staining, in 
addition to the antibodies reported above, I used anti-Myc C-33 (Santa Cruz), anti- 
PML PGM3 (kind gift of P.G. Pelicci), anti-20S proteasome PW-8265 (Affiniti 
Research Products) and anti-CBP/p300 N M II (BD Biosciences) monoclonal 
antibodies to perform co-localization experiments.
2.6-Chromatin Immunoprécipitation (ChIP)
MEFs at passage 9 were plated 7-9x10^ in 100mm Petri dish, in 8ml DMEM 
20% FBS. When 80% confluent, cells were synchronized by starvation in DMEM 
0.1% FBS, for at least 72 hrs; then 20% FBS DMEM was re-added and ChIP was 
performed at 0, 6, 12, 16 and 20 hrs post re-induction. When using NIH-3T3, cells 
were grown in 10% FBS, synchronized in low serum for 48 hrs, and harvested before 
or 3 hrs post-reinduction. The cell extract from I dish was used at each time point.
2.6.1-Protein/DNA cross-linking
Cells were fixed by adding 800//1 (I/IOVol) of cross-linking solution (11% 
formaldehyde, O.IM NaCl, ImM Na-EDTA pH 8, 0.5mM Na-EGTA pH 8, 500nM 
Hepes pH 8), and by leaving cells in the incubator at 37°C for an additional 20 min. 
The cross-linking reaction was stopped by addition of 10ml of quenching solution
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(0.125M Glycine in Phosphate-Buffered Saline, (PBS)) and 2-3 minutes incubation at 
room temperature (RT). Plates were put on ice and washed once with ice-cold 0.5mM 
PMSF in PBS.
All of the steps reported below were performed on ice. 1ml buffer A (0.25% 
Triton X-100, lOmM Na-EDTA pH 8, 0.5mM Na-EGTA pH 8, lOmM Tris-Cl pH 8, 
0.5mM PMSF, lO/^g/ml aprotinin, 10//g/ml leupeptin, 5mg/ml pepstatin, O.lmM 
sodium orthovanadate, ImM tetra-Sodium pyrophosphate, ImM NaF) was added, 
cells were scraped and collected in final 10ml buffer A/dish in a 15ml tube. After 10 
min incubation at 4°C on a rotating wheel, cells were centrifuged for 5 min at 1,500 
rpm, and the pellet was resuspended in 10ml of buffer B (0.2M NaCl, lOmM Na- 
EDTA pH 8, 0.5mM Na-EGTA pH 8, lOmM Tris-HCl pH 8, 0.5mM PMSF, 10//g/ml 
aprotinin, 10/ig/ml leupeptin, 5mg/ml pepstatin, O.lmM sodium orthovanadate, ImM 
tetra-Sodium pyrophosphate, ImM NaF). Incubation and centrifugation steps were 
then repeated, and the pellet was resuspended in 440//1 of sonication buffer (0.2M 
NaCl, lOmM Na-EDTA pH 8, 0.5mM Na-EGTA pH 8, lOmM Tris-Cl pH 8, 0.5mM 
PMSF, lO/rg/ml aprotinin, lO/^g/ml leupeptin, 5mg/ml pepstatin, ImM sodium 
orthovanadate, lOmM tetra-Sodium pyrophosphate, lOmM NaF). Samples were 
sonicated for 3x30 sec, yielding genomic DNA fragments with a bulk size of 500- 
2000 base pairs, and the sonication buffer was adjusted to a RIPA buffer by adding 
1% Triton X-IOO, 0.1% Sodium Dodecyl Sulphate (SDS), and 0.1% Sodium 
Deoxycholate (DOC) final concentration. Samples were incubated for 10 min on a 
rotating wheel at 4°C and then centrifuged for 10 min at 10,000 rpm. 50//l/sample 
were kept to recover total DNA input, and the lysates were subjected to
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immunoprécipitation (Ip).
2.6.2-Pre-clearing
A 50% protein A-sepharose (Pharmacia)/PBS slurry was incubated in Ip buffer 
without anti-proteases and anti-phosphatases, with I mg/ml BSA and 0.25mg/ml 
sheared Salmon sperm final concentration, for 2hrs to o.n. at 4°C on a wheel. 80//1 of 
blocked protein A beads were then added to the lysates and incubated for 30 min-1 hr 
at 4°C on a wheel and centrifuged for 2 min at 5,000 rpm at 4°C.
2.6.3-Immunoprecipitation
Supernatants were transferred to new tubes and incubated o.n., either with 2/rg 
of anti-Myc N-262 polyclonal antibody (Santa Cruz), or without antibody, at 4°C on a 
wheel. Immune complexes were recovered by adding 80//1 of blocked protein A-beads 
and incubated Ihr at 4°C on a wheel. Beads were washed for 5 times in RIPA buffer, 
once with Li Cl buffer (0.25M Li Cl, 0.5% NP-40, 0.5% DOC, lOmM Tris-Cl pH 8, 
ImM Na-EDTA pH 8, O.lmM PMSF, IO//g/ml aprotinin, IO//g/ml leupeptin, 5/ig/ml 
pepstatin or cocktail inhibitor SIGMA, cat.n.P8340, O.lmM sodium orthovanadate, 
ImM tetra-Sodium pyrophosphate, ImM NaF) and twice with TE buffer. DNA- 
protein complexes were eluted by adding 250/d of elution buffer (1% SDS, 0.1% 
NaHCOg) and incubated for 15 min on a wheel at RT. After I min centrifugation at 
5,000 rpm at RT, supernatant was transferred to a new tube and elution was repeated.
2.6.4-Reversal of cross-linking
In order to revert cross-linking, NaCl 0.2M final concentration was added to
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Chip samples and DNA input, and incubated o.n. at 65°C. Proteins were then digested 
by incubating for Ihr at 45°C after adding 20piM Tris-Cl pH 6.5 and 0.8mg/ml 
proteinase K final concentration, and extracted once with phenol chloroform and once 
with chloroform. DNA was precipitated in 2.5Vol ethanol 100%, I/IOVol 3M Na- 
Acetate pH 4.8, and 20pig glycogen, washed with ethanol 70%, centrifuged for 2 min 
at 12,000 rpm and resuspended in TE, 50//1 for input DNA samples and 100/^1 for 
Chip DNA.
2.6.5-PCR reaction on ChIP samples
l-2pi\ of Chip DNA was used for PCR analysis. PCR was performed in final 
25pi\ sample containing 2.5//1 of I Ox PCR buffer, 0.25//1 of HotStarTaq (Qiagen), 
0.2mM dNTPs, 800nM forward and reverse primers, and, when required, 5pi\ of 5x Q 
solution (Qiagen). The following primer pairs were used: (gene name: forward primer 
and reverse primer) Adm: cagggcaggtctggttttag and tccaagattgactgcgatga; B23: 
gttggggaggatacatctgc and gttggctagagtcggagagc; Bax: gcgcatgcgttcatttagta and
gaggggtcctagggttcttg; BN5IT: ggtgacggagtccaaagcta and tccttccgacatggttccta; Cad: 
tgctgtggaaccatcctatg and cactggaaccaagcgaacac; Cav-I: ctctgctgccagaaccttg and
tccctgggctgtgatttaag; Cdc25a: tgatccagcaggaaacagag and ggggtgaacaagacaggatg; 
Cdk4: gcccactcagagacccatag and gggaagcagaggtgtggtta; C ull: gccctcttctggagtgtctg 
and atcaacgcatgggatacctc; CcnbI: gaaacgcattctacgggaac and aatcagaggttccccgattc; 
Ccndl: acccattctcccggtttaag and cggactgcttctctccaaac; Ccnd2: ttaagcgtccctgatcatcc and 
cgtttcctcacctccttcct; Eca39: atcactggaggggatcacag and ctgggtgcaaatgtgagtct; Eca40: 
aaccatgaacccttccacac and cgtccaaactcagaggaagc; Eif2a: gggcagtgactcttcagctc and 
gaggagactcggaacaccaa; Eif4e: acagaaggcacagcaggaat and aggcttctgggaagtggagt. or
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aaaaagactccacttcccagaa and gttccacagtcgccattttag; Fth: cacactcacacaggctcctc and 
caagcactgttgaagcagga; Gadd45: caactctgccttgctttggt and ctagcctcgctggggaact; 
HspTO.l: gagacatggacaagcaagca and g g tgg tgagag tg tgggac t; IsgfSg:
cccaaggtgctactgctgac and cttacctgagccgctgaaaa; LDH-A: cttctgaggctgaggagcat and 
ggggccttaaatggaagc; Ddxl8: attcggtctccaaagggaac and cattccgcttctcgatcttc; Neu: 
gcgacaaacccattatctgg and tgctcccagcttcactttct, or agtgggtgagaactgcaagc and 
ctcagctccacaacttcacg; Nucleolin: ggaagagagggccaacctta and ctgcttcccactttctctcg; Ode: 
caccgtgctgtgaggtga and gcaagtggagcgctgagt; Cdkn2b: caccgaagctactgggtctc and 
gttcagggcgttgggatct; Cdkn2a: tcttctctgcgcgctgttc and ctttcgggtcccgaaacttt; Cdknla: 
cgctgcgtgacaagagaata and tcgagctgcctccttatagc; Cdknlb: agcctacgctccgactgtt and 
agttctgcgactgcacacag; Trp53: ctccatttcttgccctcaac and gtgccccctaactgtagtcg; Pdgfr: 
gggggaaaagaaagagagga and acaccactgtgggctttctc; Ptma: atccccgtagcgaaaactct and 
cggaggaggacaatgaaca, or ctggtatgaaagcggacctc and cctgcctaggaccccact; RCL: 
acggggaggagtcagaactaa and ccgcagaagtacacagagca, or gtgtacttctgcgggagcat and 
ctagtcagccggtcccctta; Tert: tggctcagagtcgtgtcatt and ctcaactcacgcacccatag; or 
tctaagcacacccttgcatc and gcaaccaaagtgcggtagat; TMP: ctgcattctggagccaactt and 
aagcaaacacagccgagtg; Thbsl: taaagggtcttaggtggtcccc and agctctcgggctgaaagtga; 
PML.l: gcagctctgaattcctggtc and gcttttccctgtctgtgagc; PML.2: cggatctttccttgttctgc and 
gccagaaaactgagcgagag.
2.7-RNA extraction and Real-Time PCR analysis
Total RNA for each time point was extracted from  80% confluent 
synchronized MEFs cells in a 100mm Petri dish with RNeasy mini Kit (Qiagen). Total 
RNA was quantified by spectrophotometer analysis, diluted to 100ng///l final
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concentration, and checked again by UV detection after running 4^\ of each sample 
with 1/d of 5x RNA loading buffer (10ml solution: 80//1 of 500mM EDTA pH 8, 
720//1 of 37% formaldehyde, 2ml glycerol, 3084//1 formamide, 20mM 3-[N- 
morpholino] propanesulfonic acid (MOPS), 5mM sodium acetate, InM EDTA, and 
some bromophenol blue powder, in 10ml final volume of RNAse-free water) on a 
formaldehyde gel (1.2g agarose, 20mM 3-{N-morpholino}propanesulfonic acid 
(MOPS), 5mM sodium acetate, and InM EDTA in 100ml final volume of RNAse-free 
water, and brought at pH 7.0 with NaOH) run in a formaldehyde gel running buffer 
(20ml of 37% formaldehyde, 20mM 3-{N-morpholino}propanesulfonic acid (MOPS), 
5mM sodium acetate, InM EDTA, and 980ml of RNAse-free water). cDNA was 
prepared using l//g  total RNA, 200pmol random hexamers (Invitrogen) and 
Omniscript reverse transcriptase (Qiagen) according to manufacturer’s instructions, in 
30//1 final volume. Gene expression profile was achieved by performing Real-Time 
quantitative PCR on an Applied Biosystems 7000 machine, in 20//1 final sample, 
containing 1:3 dilution of each cDNA sample, 2x Sybr Green Master Mix (Applied 
Biosystems), and 300nM forward and reverse primers, which were designed on 
different exons in order to avoid that potential genomic contamination could alter gene 
quantification. Every sample was loaded in triplicate.
The following primer pairs were used: (gene name: forward primer and reverse 
prim ers;) Adm: gactcgctgatgagacgaca and tag a tc tg g tg g g ccaa ttt; B23:
cctcatggaagactcgatgg and tcattgcttctgcctctacg; Bax: agaggcagcggcagtgat and 
cctggatgaaaccctgtagc; BN51T: cgaagagaccaagcagatcc and gcacgtccacctccatatct; Cad: 
taaagagaagccacccagga and gcttgacagacaggatgtgc ; Cav-1: atgtctgggggcaaatacg and
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acgtcgtcgttgagatgctt; Cdc25a: gactgtcccctgtcaccaac and cgtcagggaaatttcaaggt; Cdk4: 
aggcctttgaacatcccaat and caggccgcttagaaactgac; C ull: tcctcatggactgaagcaga and 
tgacttggaaggagggactc; Ccnbl: cgctcagggtcactaggaaca and agcgtttttgcttcccttttc; Ccndl: 
gcgtaccctgacaccaatct and ctcttcgcacttctgctcct; Ccnd2: tcgatgattgcaactggaag and 
atgctgctcttgacggaact; Eca39: actcacatttgcacccagga and agctccaaagaccagcgaat; Eca40: 
actggacccatgaagacgga and tgcctgagccgaagacttct; Eif2a: cgagacgacgtatccgttcta and 
caacatggcgaagaatgcta; Eif4e: ggcaagcaaaccttcgattg and ccgtctctgctgcttgttca; Fth: 
gccagaactaccaccaggac and tggttctgcagcttcatcag; Gadd45: gaagaccgaaaggatggaca and 
tgagggtgaaatggatctgc; HspTO.l: gagacatggacaagcaagca and ggtggtgagagtgtgggact; 
Id2: ccccagaacaagaaggtgacc and gaagggaattcagatgcctgc; Isgf3g: gaccaggatgctgccatatt 
and gttcctgctggcagtattcg; LDH-A: agcttgcccttgttgacgtc and cgtttcgctggaccaggtt; 
Ddxl8: ctggcaagatgtcgcagtta and ctgagtccacaggcacagaa; Neu: accggtaccgacatgaagtt 
and tgtttcactcggttgtgagc; Nucleolin: tgacagcagtggagaagagg and ggaatgactttggctggtgt; 
Ode: tgattccatctccaggttcc and gccacctcagatgcttcttt; Cdkn2b: agatcccaacgccctgaac and 
aggcgtcacacacatccag; Cdkn2a: gctctggctttcgtgaacatg and cgtgtccaggaagccttcc; 
C d k n la : c ttg tc g c tg tc ttg c a c tc  and c tcc tg a cc c ac a g ca g a ag ; C d k n lb :
cgcaggagagccaggatgt and gcccttttgttttgcgaaga; Trp53: tgctcaccctggctaaagtt and 
cctgaaaatgtctcctggct; Pdgfr: ggggcttccaggagtgatac and gggacatctgttcccacatc; Ptma: 
ggataccagctccgagatca and accgtcaccttcttcctcct; Rcl: agtgacacagccatccctgg and 
gcctcaaagtaccgatggagc; Tert: atctaccgcactttggttgc and aagcagctcaaagccaaaag; TMP: 
gaagtcaccaaaaagccaaga and cttcattgccgtaggacagg; Ybxl: gagaagtgatggagggtgctg and 
gataccgacgttgaggtggc; Thbsl: actcggggcaggaagactat and tctgtgtctgcttggtcagg; JPO-1: 
accgctctctgggttctaca and cagttgcaaattcctcgaca; T k l: aatttttccacccacggact and
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acttgtactgggcgatctgg; PML: cagaggaaccctccgaagac and ccaggagccttgcagatg; Myc: 
ctcctcgagctgtttgaagg and agcagctcgaatttcttcca; Gapd: ggtgaaggtcggtgtgaacgg and 
gtggtgcaggatgcattgctg, or Gapd: ggtgctgagtatgtcgtgga and ctaagcagttggtggtgcag.
Gene expression profiles were obtained by Real-Time relative quantification, 
and Gapd was used as a reference gene to quantify the expression levels of the gene 
analysed. The expression profile of each gene is the mean of at least three independent 
experiments. I could not analyse the expression profile of HspTO.l, as this gene is 
present in the mouse genome in multiple copies, most of which are probably 
pseudogenes that are not distinguishable by RT PCR analysis, and thus failed to 
undergo quantitative assay. Instead, I decided to include in my analysis T k l, which is 
a downstream target of Myc, even if Myc binding to its promoter region has been 
demonstrated so far only by bandshift (Pusch et al., 1997; and www.c- 
myccancergene.org).
2.8-Co-immunoprecipitation assay
Cells were transfected as reported above, at the concentration of 1x10^ 
cells/100mm Petri dish. After 36-48 hrs of transfection, cells were washed twice with 
ice-cold PBS, harvested in 0.5mM PMSF in PBS and centrifuged for 1 min at 1,000 
rpm at 4°C. Pellets were resuspended in 500//1 PTG buffer (lOmM Tris-Cl pH 8, 2mM 
DTT, 10% glycerol, ImM MgClz, ImM PMSF, cocktail inhibitor SIGMA 
cat.n.P8340, ImM sodium ortho vanadate, lOmM tetra-Sodium pyrophosphate, lOmM 
NaF) and incubated for 10 min on ice; then 0.5% NP-40 final concentration was
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added, samples were incubated for 3-4 min on a wheel at 4°C and centrifuged for 5 
min at 800 rpm at 4°C. Nuclei were resuspended in Ip buffer (0.25% NP-40, 2mM 
DTT, cocktail inhibitor SIGMA, ImM PMSF, ImM sodium orthovanadate, lOmM 
tetra-Sodium pyrophosphate, lOmM NaF in PBS), sonicated for 3x5 sec on ice, 
incubated for 30 min on a wheel at 4°C and centrifuged for 5 min at 14,000 rpm at 
4°C. Total lysates were immunoprecipitated for 3 hrs at 4°C on a wheel with the 
required antibodies, followed by Ihr incubation with 40//1 of 50% protein A- 
sepharose/PBS.
Beads were washed three times with Ip buffer, resuspended in final Ix Laemli 
buffer, and loaded onto 7.5% SDS-polyacrylamide gel. Biorad mini-gel equipment 
was used in accordance with the manufactures instructions. Proteins were transferred 
on PVDF membranes (Pharmacia), subjected to Western blot analysis using 1:500 
final concentration of anti-Myc N-262 antibody or anti-PML H-238 antibody, and 
revealed by chemiluminescence using Super Signal Pico (Pierce).
2.9-GST pull-down
2.9.1-Constructs for GST pull-down
Three different constructs were used for the GST pull-down assay. These 
constructs corresponded to three different portions of Myc, corresponding to aa 1-178, 
173-349 and 104-349, fused with its 5’ to the Glutathione S-Transferase moiety. These 
Myc fragments were obtained by PCR amplification with Vent polymerase using 
specific primers, and subcloned into a pGEX-4Tl vector (EcoRI-XhoI), so that the 
protein products are fused at N-terminus to the GST protein. The three constructs and
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the empty vector were used to transform Escherichia Coli strain DH5a on LB plates 
with lOOpiM ampicillin.
2.9.2-Expression and purification of GST-Myc chimeric proteins
Colonies were inoculated into 5ml LB medium with ampicillin and incubated 
overnight at 37°C with vigorous shaking. The morning after the cultures were diluted 
1:20 in 100ml LB medium with ampicillin and grown at 37°C until their OD^go was 
0.5-0.8. After removing 2ml as a control, the bacterial cultures were induced to 
express the fusion proteins by adding O.lmM IPTG. Cells were grown for 3 hours at 
37°C. Bacterial samples (2ml of uninduced and 1 ml of induced bacteria) were 
centrifuged to pellet cells, which were then resuspended in 100/d of 2x Final Sample 
Buffer (FBS) (250mM Tris-HCl pH 6.8, 35% glycerol, lOOmM DTT, 2% SDS, 0.2% 
bromophenol blue). Samples were boiled for 5 min, and fractionated by SDS-PAGE 
and the protein gel was stained with Blue-Comassie (0.1 % Comassie Blue, 40 % 
Methanol, 10 % acetic acid in H^O) for 15 min and destained with a destaning solution 
(40 % Methanol, 10 % acetic acid in HjO).
Once checked that the fusion proteins were induced, all the cultures were 
centrifuged 10 min at 3,500g to pellet the cells. Cells were resuspended in 1.8ml lysis 
buffer (50mM Tris-HCl pH 8, 200mM NaCl, ImM EDTA, ImM DTT, ImM PMSF, 
20//1 cocktail inhibitor SIGMA), and sonicated 30x5 sec. Then 1% Triton x-100 final 
concentration was added, the lysates were incubated 30 min at 4°C on a rotating 
wheel, and centrifuged 30 min at 14,000 rpm at 4°C. Supernatants were collected, 
transferred to new tubes and supplemented with lOO/il of Glutathione-Agarose slurry
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and incubated overnight at 4°C on a rotating wheel. Beads were washed 4 times with 
1ml washing buffer (IxPBS, ImM PMSF, cocktail inhibitor SIGMA), and 20//1 were 
checked through SDS/PAGE and Comassie staining.
2.9.3-GST pull-down assay
Three Petri dishes of HeLa cells were transfected with human PML isoform IV 
cloned into a pCDNA3-HA as reported above, at the concentration of 1x10^ 
cells/plate. Cells were collected and resuspended in 600/d lysis buffer (50mM Tris- 
HCl pH 7.5, ImM EDTA, 200mM NaCl, 0.5mM DTT, 1% Triton x-100, ImM PMSF, 
30/^ 1 cocktail inhibitor SIGMA), sonicated 3x5 sec and kept on a rotating wheel for 30 
min. The sample was centrifuged at 14,000 rpm for 30 min, and the supernatant was 
divided into 4 new tubes and supplemented with the agarose beads bound to GST 
alone or to the specific GST-fusion proteins, and incubated overnight at 4°C. Samples 
were then centrifuged at l,500g for 4 min and beads were washed 4 times in the lysis 
buffer. After the last wash, beads were resuspended in 2xFBS, boiled for 5 min, and 
subjected to by SDS/PAGE. Proteins were transferred on PVDF membranes 
(Pharmacia), and Western blot analysis was performed using 1:500 final concentration 
of anti-PML H-238 antibody, and revealed by chemiluminescence using Super Signal 
Pico (Pierce).
2.10-Iinmunoprecipitation of endogenous Myc in MEFs
Endogenous Myc protein levels at each time point were determined through 
immunoprécipitation. Two properly synchronized MEFs Petri dishes were used at
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each time point. Cells were harvested, subjected to nuclear extraction (see above), and 
the nuclei were resuspended in RIPA buffer, sonicated three times for 5 sec on ice, 
incubated 30 min on a wheel at 4°C and centrifuged 5 min at 14,000 rpm at 4°C. 
Following protein quantification (see below), equal amounts of lysates were 
immunoprecipitated 3 hrs at 4°C on a wheel with 5//1 anti-Myc N-262 antibody, 
followed by 1 hr incubation with 40//1 of 50% protein A-sepharose slurry. Beads were 
recovered after centrifuging 1 min at 1,000 rpm and resuspended in Laemli buffer Ix 
final concentration, loaded onto a 7.5% SDS polyacrylamide gel and transferred on a 
membrane as described above.
Western blot analysis was performed using 1:500 final concentration of anti- 
Myc N-262 antibody.
2.11-Proteasome inhibition
Proteasome inhibitor M G-132 (Sigma) was stocked at the concentration of 
lOmM in DMSO. When added, it was diluted to the final concentration of 50//M in 
the culture medium 5 hours before immunoprécipitation or immunofluorescence 
assays were performed.
2.12-Protein quantification
Protein concentrations were determined using Bradford’s method (Bradford, 1976). 
Protein samples were mixed with Bradford’s reagent (Biorad) and the absorbance at 595 
nm was measured on a spectrophotometer. Protein absorbance was converted to mg/ml
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concentration using a standard curve constructed by measuring the absorbance of a range 
of bovine serum albumin (BSA) concentrations.
2.13-Myc stability assay
Proliferating cells were induced to undergo block of translation by adding 
cycloheximide at the final concentration of 10//g/ml, in the culture medium. At the 
established time points, cells were harvested, and endogenous Myc was 
immunoprecipitated and revealed as described above.
2.14-Western Blot analysis
Polypeptides separated by SDS/PAGE were transferred to a Hybond-P polyvinylidene 
difluoride (PVDF) transfer membrane optimised for protein transfer (Amersham 
Pharmacia Biotech), using a wet blotter (Biorad). The membranes were blocked with 
PBS containing 5% non-fat dry milk powder and 0.1% Tween-20, then incubated with 
monoclonal or polyclonal antibodies diluted in blocking buffer in PBS containing 
0.1% Tween-20. Horseradish peroxidase conjugated anti-mouse IgG and anti-rabbit 
IgG (Amersham) were used as secondary antibodies. Protein detection was obtained 
by chemiluminescence using Super Signal Pico (Pierce).
2.15-Immunofluorescence staining
In order to perform immunofluorescence assays, 20,000 cells/well were plated 
in 8-well-chamber slides. When transfected, 200ng of Myc, PML and CBP expression 
vectors were used. After transfection, cells were grown on cover slips for 36-48 hrs,
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washed twice with PBS and fixed with 4% paraformaldehyde in PBS for 5 min at RT. 
Cells were rinsed twice with PBS, permeabilised in 0.2% Triton X-100 in PBS for 30 
min at RT, and blocked for 1 hr in 0.1% Triton X-100 in PBS containing 10% heat- 
inactivated goat serum. Cells were incubated for 3 hrs at RT (or o.n. at 4°C) with 
primary antibodies diluted in blocking buffer, followed by 1 hr incubation at RT (or 
30 min at 37°C) alternatively with FITC-conjugated anti-mouse and/or TRITC- 
conjugated anti-rabbit antibodies (Dako Glostrup) or with Cy2-conjugated anti-rabbit 
antibodies and/or Cy3-conjugated anti-mouse antibodies (Jackson ImmunoResearch), 
followed by two washes with PBS. In some cases, to detect nuclei, cells were stained 
using DNA specific stain DAPI (Roche).
2.15.1-Biotin-streptavidin amplification system
To detect endogenous Myc protein, a biotin-streptavidin amplification method 
was used. In this system, after incubation for 2 hrs at RT with polyclonal anti-Myc N- 
262 antibody, cells were incubated first with Biotin-conjugated goat anti-rabbit 
antibodies (SIGMA) for 1 hr, followed by 1 hr with Cy3-conjugated streptavidin 
(SIGMA). Cells were then stained for 5 min at RT with Hoechst 33258, washed once 
with PBS, mounted with Vecta Shield (Dako Glostrup), and observed under a Zeiss- 
Axioplan 2 microscope or Leica TCS SP2 AOBS laser scanning confocal microscope.
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CHAPTER 3: Results
3.1-Myc partially co-localizes with PML
Myc and PML are two proteins that exhibit different nuclear distributions. As 
mentioned above, PML localizes to the NB, whereas Myc shows a diffuse speckled 
sub-nuclear pattern (Yin et al., 2001). In order to investigate whether Myc localization 
might overlap with that of PML, murine c-Myc and human PML IV were co­
expressed in U20S, Cos-7 and HeLa cell lines, and immunofluorescence assays were 
performed and analysed by fluorescence microscopy (Fig.3.I). In order to rule out the 
possibility of artefacts, I co-expressed the two proteins with different viral promoters 
and at different concentrations, so that I could finally reproduce the subcellular 
localization of the endogenous proteins.
I observed that the pattern of distribution of each protein is very 
heterogeneous in the cell nuclei, which probably depends on the cell cycle stage and 
the expression levels. Myc localization is mostly diffuse throughout the nucleoplasm, 
although in some cells it seems to concentrate in discrete sub-nuclear structures 
(Fig.3.Ia, d, g). In contrast, PML was localized in the NB, which differ in number and 
size from cell to cell, often accompanied by a weak diffuse nuclear staining (Fig.3.Ib, 
e, h). Combined immunofluorescence revealed a subset of cells where Myc and PML 
signals appear to overlap partially in several NB (Fig.3.I c, f, i).
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Fig.3.1. Co-localization of transfected Myc and PML in different cell types by 
fluorescence microscopy. U20S (a-c), Cos-7 (d-f), and HeLa cells (g-i) were co­
transfected with pCMV-2-Flag-Myc and pCDNA3-HA-PML IV. Myc protein shows 
a diffuse nucleoplasmic pattern (red), whereas PML is preferentially organized into 
the NB (green). Co-localization of the two proteins is observed at some NB (yellow).
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The localization assay was also performed on untransfected cells (Fig.3.2). 
Due to the low and diffuse Myc signal, it is very difficult to evaluate a co-localization 
between the two proteins. However, several cell nuclei show a co-distribution of Myc 
with both punctuate and diffuse PML in definite subnuclear areas, suggesting that an 
interaction between the two endogenous proteins may occur. To verify this hypothesis, 
I decided to investigate further the co-localization between Myc and PML by confocal 
microscopy (Fig.3.3). Particularly, I looked at the frequency of co-localization of the 
two endogenous proteins. HeLa cells were immunostained with PGM3 anti-PML 
monoclonal antibody and N262 anti-Myc polyclonal antibody, using the biotin- 
streptavidin amplification system to increase Myc signal. Confocal analysis on the 
endogenous proteins revealed co-localization in about 10-15% of the cells, in which 
only a small but consistent fraction of Myc protein localizes to the NB (Fig.3.3 c, f, 
and enlarged squares).
45
Fig.3.2. Localization of the endogenous Myc and PML proteins.
Immunofluorecence performed on HeLa cells. In some cells, Myc localization 
(red) concentrates in discrete areas of the nucleus, possibly the nucleoli, where 
an enhanced co-localization with the PML bodies and with the diffuse fraction
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Fig.3.3. Analysis of the rate of co-localization between Myc and PML by 
confocal microscopy, (a-c and d-f) Co-localization of the endogenous proteins 
in HeLa cells. The white arrows into the enlarged squares (c% f  and f ’) indicate 
the site where PML (green) and Myc (red) signals overlap; being this co­
localization in most cases unable to cover the entire NB, we argue that Myc 
localizes only to definite areas of the NB.
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3.2-Myc physically interacts with PML
3.2.1-Myc and PML co-immunoprecipitate
In light of the partial co-localization observed by immunofluorescence 
m icroscopy, I investigated the association between Myc and PML by 
immunoprécipitation. To this end, Cos-7 (Fig.3.4) and HeLa cells (not shown) were 
co-transfected with two constructs expressing Flag-tagged Myc and HA-tagged human 
PML IV. Cell lysates were immunoprecipitated with specific antibodies, and the final 
samples were loaded on a polyacrylamide gel and subjected to SDS/PAGE. Under 
these conditions, the two proteins migrate as 63 and 85 KDa polypeptide chains, 
respectively.
As shown in Fig. 3.4, when lysates were immunoprecipitated with anti-Flag or 
anti-Myc antibody, a small portion of PML was recovered (Fig.3.4a, lanes 2 and 3). 
Likewise, immunoprécipitation of PML by addition of anti-PML or anti-HA antibody 
to the samples determined co-immunoprecipitation (co-IP) of Myc (Fig.3.4b, lanes 1 
and 4). Immunoprécipitation with the control antibody failed to recover either Myc or 
PML proteins (Fig.3.4a and b, lanes 5 and 6).
To investigate the interaction further, I performed co-IP experiments in cells 
that over-expressed only one of the two proteins. When transfected in NIH-3T3 
murine fibroblasts, PML was recovered after immunoprécipitation of endogenous Myc 
(Fig.3.5, lane 5). However, I could not reproduce the complementary result by 
immunoprecipitating endogenous PML in Myc transfected cells. This may be due to 
the stoichiometry of the complex. In fact, it may be that immunoprécipitation with
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anti-Myc antibody co-precipitates not only PML protein directly involved in the 
interaction, but also PML contained in the NB where Myc docks, thus enriching PML 
recovery. This could also explain why I failed to perceive a detectable amount of Myc 
protein after immunoprécipitation with anti-PML. Also, the very low extent of 
endogenous Myc-PML co-localization, and presumably the dynamic nature of their 
interaction, impeded the co-IP of the endogenous proteins. Due to the ability of both 
Myc and PML to bind multiple partner proteins, and considering that all of the co- 
immunoprecipitation experiments were conducted in low stringency buffers, I cannot 
rule out the possibility that Myc and PML association might not be direct, but rather 
mediated by the presence of cofactors.
3.2.2-Myc and PML interact by GST pull-down assay
The interaction between the two proteins was also assessed via GST pull-down assay. 
In this experiment, three different fragments of Myc, spanning the entire protein 
length, were fused to a GST moiety, expressed in E.Coli, and affinity-purified with a 
glutathione-sepharose slurry, as confirmed by Comassie staining after loading an 
aliquot of each sample on gel (Fig 3.6a). The resins were then incubated with cellular 
extracts from HeLa cells transfected with PML, loaded on a gel, and immunoblot 
analysis was performed with anti-PML antibody. As shown in Fig.3.6b, PML 
specifically interacts with the N-terminal portion of Myc, but neither with the other 
protein fragments, nor with the GST moiety alone (not shown). The protein fragment 
interacting with PML includes both Myc N-terminal domains, Myc Box I and Box II,
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respectively. As Myc Box II is also part of a protein segment that does not show 
interaction with PML, it is probable that the interaction between the two proteins is 
mediated by the Box I, or that both domains are required for the interaction with PML.
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FL -Myc: + + + + +
HA-PML: + + + + + +
a-myc: - - + - - -
ct-PML: - - - - -
a  -H A: + - - - - -
ct -FL: - + - - - -
mouse IgG - - - - + -
rabIMt IgG - - - - - +
PML->
Western 
Blot :
a  -PML a
Myc->
Western 
Blot :
a  -Myc
Fig.3.4. Myc and PML interact in vivo, (a, b) pCDNA3HA-PML IV and pCMV- 
2-Flag-Myc were co-transfected in Cos-7 cells and immunoprecipitated with 
antibodies that specifically recognize the two proteins or the two tags, or with 
unrelated antibodies. Samples were subjected to 7.5%-SDS-PAGE and electro­
blotted on a Hybond nylon membrane. Western blot was performed with anti-PML 
H-238 (a) and anti-Myc N-262 (b) specific antibodies.
FL -Myc: + + + + - +
HA-PML: -f + 4 - + -
OL - myc: + - - - + -
CL -PML: - + - - -
mouse IgG: - - + - - -
rabbit IgG - - - + - -
PML->
Western 
Blot :
a  -PML
Fig.3.5. Transiently expressed PML is immunoprecipitated by endogenous 
Myc. NIH-3T3 mouse fibroblasts were transfected with HA-PML IV and Flag- 
Myc together (lane 1 to 4) or separately (lane 5 and 6) and immunoprecipitated 
with anti-Myc, anti-PML or unrelated antibodies. Western blot was performed 
with anti-PML antibody. Transfected PML is immunoprecipitated by both 
transfected (lanel) and endogenous Myc (laneS).
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Fig.3.6. PML interacts with Myc by GST pull-down assay. Three 
recombinant GST-Myc fusion proteins, bearing different domains of Myc and 
covering the entire protein length, were produced in E.Coli, purified on a 
Glutathione-sepharose slurry (a), and incubated with a protein lysate obtained 
from PML-transfected HeLa cells.
Samples were loaded on a polyacrylamide gel, electro-blotted on a membrane, 
and analysed by Western Blot with an anti-PML antibody (b).
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3.3-Myc-PML association increases upon proteasome inhibition.
Besides its diffuse nucleoplasmic staining, Myc can also distribute around the 
nucleoli. When over-expressed, the rate of Myc localization to the nucleoli increases, 
and the same effect is observed if cells are treated with proteasome inhibitors (Arabi et 
al., 2003). Recent evidences have demonstrated the recruitment of PML to the 
perinucleolar zone following proteasome inhibition (Mattsson et al., 2001). I observed 
that the nucleolar distribution of over-expressed Myc induced PML sequestration at 
the nucleoli in several cells (Fig.3.7A). Therefore, I hypothesized that Myc-PML 
interaction might be sensitive to the turnover determined by the proteasome-mediated 
degradation. To test this, HeLa, Cos-7, and U20S cells where transfected with Myc, 
and incubated for 5 hours with 50pM M G-132 in DMSO or with DMSO alone. Over­
expressed Myc showed the classical nucleoplasmic diffuse and nucleolar pattern, both 
in untreated or DMSO-treated cells. However, cells treated with the proteasome 
inhibitor showed an increased distribution of Myc around the nucleoli and in well- 
defined nuclear speckles (Fig.3.7B, a-c). As the proteasome co-localizes with Myc at 
the nucleoli after proteasome inhibition, I checked whether this localization is also 
extended to Myc-containing nuclear speckles. We observed a strong re-localization of 
the proteasome in Myc nuclear inclusions, which was undetectable in untransfected 
cells (Fig.3.7B, d-f). To further confirm the specificity of the effect observed, cells 
were co-transfected with Myc and CBP, or with PML and GBP. After proteasome 
inhibition, Myc re-localized in the nuclear speckles, whereas CBP does not (Fig.3.7B, 
g-i); furthermore, this effect was never observed in PML and CBP co-transfected cells
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(Fig.3.7B, j-1). Upon Myc transfection, endogenous PML showed a remarkable 
redistribution into Myc-enriched structures. PML strongly co-localized with Myc in 
the perinucleolar region and almost completely in Myc-containing speckles, whereas 
PML localization was not affected by proteasome inhibition in untransfected cells 
(Fig.3.7C, a-c). Then, I checked if Myc re-localization with PML after cell treatment 
with the proteasome inhibitor corresponded to increased interaction. HeLa cells co­
transfected with Myc and PML, and treated with MG-132, showed a clear enrichment 
of Myc-PML co-immunoprecipitation, using either anti-Myc or anti-PML antibodies 
(Fig.3.8), thus confirming that proteasome inhibition stabilizes the Myc-PML 
complex.
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PML
A
Fig.3.7A. Myc-PML association increases at the nucleoli. Perinucleo lar 
accumulation of Myc (green) in a small percentage of Myc-transfected HeLa cells 
induces mislocalization of endogenous PML (red) at the nucleoli.
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Fig.3.7B. Myc nuclear localization is influenced by inhibition of protein  
degradation, (a-c) Myc nuclear localization in Cos-7 cells untreated (a) or treated 
as indicated (b-c). (d-1) U20S cells were transfected with Myc alone (d-f), or co­
transfected with Myc and CBP (g-I), or with PML and CBP (j-1), treated with 
MG132, and subjected to immunofluorescence staining as indicated, pr.inh.: 
proteasome inhibitor; 20S: 20S proteasome subunit.
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Fig.3.7C. Myc-PML association increases upon proteasome inhibition. HeLa 
cells transfected with Myc and subjected to immunofluorescence assay as indicated. 
PML shows increased relocalization with transfected Myc at the nucleoli and at 
well-defined nuclear inclusions.
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FL-Myc + 4- 4- 4_ 4* 4*
HA-Pni + 4- 4- 4- 4- 4-
a-Myc + - - 4- - -
a-PML * 4- - - 4- -
Rabbit IgG _  1 _ 4" - - 4-
MG-13250pM 4- 4* 4- - - -
PML
Myc
WB: a-P M L
WB: a -M y c
Fig.3.8. M yc-PM L physical in teraction is increased by proteasom e 
inhibition. HA-PML and Flag-Myc were co-transfected in HeLa cells, 
immunoprecipitated with the indicated antibodies in presence or absence 
of the proteasome inhibitor, and analysed by Western Blot.
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3.4-PML enhances Myc induced expression of an E-Box driven reporter gene
As mentioned above, PML is deeply involved in the regulation of gene expression by 
modifying transcription factor activity. Therefore, I investigated the role of PML in 
the main tasks of Myc: DNA binding and regulation of target gene expression.
As a preliminary assay, I tested the ability of PML to influence Myc transactivation 
properties. HeLa and HepG2 cells were transfected with Myc and PML constructs, 
and with a reporter vector that bears 4 E-boxes upstream of the minimal Tk promoter 
that drives expression of the firefly luciferase reporter gene (Vervoorts et al., 2003). 
As shown in Fig.3.9, PML enhances the transcriptional response of Myc, resulting in a 
2- to 3-fold increase of luciferase activity compared to the expression of the reporter 
gene by Myc alone. The same results were observed in HEK 293 cells (data not 
shown). PML showed negligible influence on the expression of the E-box driven 
luciferase in the absence of Myc. These results show that PML influences the 
transcriptional activity of Myc.
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f i * l l  i v p * *
HepG2
Fig.3.9. Transactivation assay. HeLa and HepG2 cells were 
transfected with a luciferase reporter gene driven by 4 E-box 
elements, and luciferase activity was measured after co-transfection 
with pCMV-2-Flag-Myc and pCDNA3-HA-PML IV ( |B ) ,  pCMV- 
2-Flag-Myc and pCDNA3-HA pCMV-2-Flag and pCDNA3- 
HA-PML IV ( ) or pCMV-2-Flag and pCDNA3-HA ( H ) .
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3.5-Selection of the cell-system and of the Myc target genes to be analysed by 
Chip and Real-Time PCR
In order to investigate more extensively the role that PML plays in Myc 
transcriptional activity, I decided to perform a widespread in vivo comparative analysis 
of expression levels and promoter occupancy of Myc direct target genes. Particularly, I 
took advantage of wt and PML-/- MEFs, where the PML gene has been knocked out 
(Wang et al., 1998a). In this way, I could compare the efficiency of Myc 
transcriptional properties in two cell types that differ only for the presence of the PML 
loci.
3.5.1-Myc and PML co-localize in MEFs
The suitability of MEF cell-system for our studies was evaluated by 
immunolocalization and gene-expression analysis (Fig.3.10 and 3.11, respectively). 
Immunofluorescence assay confirmed that, following co-transfection of Myc and PML 
in wt MEFs, Myc protein localizes to the NB (Fig.3.10).
3.5.2-wt and PML-/- MEFs show the same timing of cell-cycle re-entry 
from quiescence
c-myc is an early serum-response gene, being immediately expressed by cells 
that exit their quiescent state, c-myc expression peaks in the early G1 phase and 
rapidly decreases as cells enter the S phase (Henriksson and Luscher, 1996). 
Therefore, I was interested in monitoring the events that occur during that time span
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(Fig.3.11). To do this, wt and PML-/- MEFs were synchronized by serum starvation 
and induced to re-enter the cell cycle. Cells were harvested while still in the GO phase 
(to time point) and 6, 12, 16 and 20 hours after serum addition. This protocol allowed 
me to follow the whole of the G1 and part of the S phase.
The efficacy of synchronization and the comparable timing of cell phases 
between the two cell types were assessed by using Real-Time quantitative PCR to 
monitor the expression profile of c-myc, and of Ccnbl, the gene that encodes for 
cyclin B l. c-myc expression peaks in the early G1 and returns to basal levels in the 
late G l/S phase, while Ccnbl is strongly expressed by the late S/G2 phase. In my cell 
culture conditions, the expression profile of these genes accounts for a comparable 
length of the G1 phase that follows the exit from GO in the two cell lines (Fig.3.11). 
Finally, I monitored the proper expression of PML mRNA in wt MEFs, which has 
been reported to be expressed during G1 and to decrease by the S phase (Chang et al., 
1995).
To ensure that Myc was equally represented in both wt and PML-/- MEFs, I 
checked c-myc transcription and translation in the two cell types. As Fig.3.11 shows, 
c-myc mRNA expression levels are comparable in the two cell types. In order to 
analyse Myc protein levels, Myc was immunoprecipitated from wt and PML-/- 
synchronized MEFs at the selected time points. In parallel, I also surveyed Myc 
protein stability in the two cell types. Proliferating wt and PML-/- MEFs were 
incubated with 10//g/ml cycloheximide to block protein synthesis, and subjected to 
immunoprécipitation before adding cycloheximide (nt), and 30 or 60 minutes after 
drug addition. As shown in Fig.3.12A and B, both experiments didn’t show significant
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differences, even if, at a more careful analysis, Myc seems slightly more stable in 
PML-/- cells.
3.5.3-Choice of Myc target genes
Once I had ensured that MEFs provided a good cell system for my studies, I 
decided to look for candidate Myc direct target genes to be chosen for chromatin 
immunoprécipitation (ChIP) and Real-Time PCR experiments. In order to obtain an 
unbiased analysis of Myc transcriptional properties, I decided to include in my study 
genes with different cellular functions, and for which Myc-mediated transcriptional 
activation or repression had already been reported. Primers were designed taking 
advantage of the PrimerS software, developed by the Whitehead Institute for 
Biomedical Research (Cambridge, MA), in order to amplify 200-300bp fragments. On 
Myc up-regulated genes, the selected primer pairs would amplify regulatory regions 
that are very close, or overlapping with the Myc-responsive E-box elements. On the 
other hand, potential down-regulated target genes were analysed by amplification of 
the promoter regions covering the TATA-box, the Inr, or other promoter sequences 
bound by transcription factors negatively influenced by Myc. A schematic view of the 
promoter and of the 5’ structure of Myc target genes is reported in Fig.3.I3.
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Fig.3.10. Co-localization of Myc and PML in MEFs. Co-staining (yellow) of 
transfected pCMV-2-Flag-Myc (red) and pCDNA3-HA-PML IV (green) is 
detectable in nearly all of the NB.
65
PML expression
s
Cyclin B l expression
j ï t s
to  te T12 T ie  T20
MEFs wt O  MEFs -/-
Fig.3.11. Expression profile in wt and PML-/- M EFs. Cells were synchronized 
by serum starvation and harvested before (tO) or 6, 12, 16, and 20 hours after cell 
cycle re-entry was induced by serum addition. After cDNA synthesis, single gene 
expression analysis was performed by Real-Time PCR using Gapd as reference 
gene, and repeated at least four times. The time point with the lowest expression 
level was used to normalize each assay.
x-axis: time points; y-axis: fold expression; wt MEFs: H ;  PML -/- MEFs:
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B
Fig.3.12. Myc protein quantification and stability in wt and PML-/- MEFs 
at the time points selected for ChIP and Real-time analysis.
(A) Myc protein levels at the selected time points. The different levels of Myc 
protein at t6 and tl6  in the two cell types were not reproducible, suggesting that 
this may be introduced by the experimental procedure. The low level of Myc 
protein in the t20 -/- sample is due to a problem of sample loading, and not to a 
reproducible difference compared to wt.
(B) Myc protein stability before (nt = not treated) and after 30 or 60 min 
incubation with lO^/g/ml cycloheximide.
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Fig.3.13. Schematic representation of the 5’ region of the selecteci Myc target genes.
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3.6-PML does not affect Myc binding to DNA, yet it influences the expression 
profile of several Myc target genes
3.6.1-Chromatin immunoprécipitation of Myc targets
Myc binding to regulatory regions was assessed for 36 genes that are proven or 
candidate Myc direct targets (www.c-myccancergene.org and Table 1) by performing 
chrom atin  im m unoprécip ita tion  (C hIP). M yc-DN A  com plexes were 
immunoprecipitated at the time points reported above after induction of cell cycle re­
entry. As negative controls, immunoprécipitation was performed without antibody as 
well as at tO, where Myc is functionally inactive and Myc protein levels are very low. 
PCR analysis on the immunoprecipitated DNA confirmed that Myc binds to all of the 
genes analysed, some of which had not been previously confirmed by ChIP (Table 1). 
Moreover, when PCR was performed using couples of primers designed outside the 
Myc-responsive region of genes like Ddxl8 and Cdknb2, no enrichment was detected, 
further confirming the specificity of the ChIP assay (data not shown).
Fig.3.14 reports the ChIP profile of 6 out of 22 Myc up-regulated genes and of 
5 out of 14 Myc down-regulated genes. I could not find any substantial difference in 
Myc binding levels between the two cell types, with the exception of a few targets 
where PCR performed on Myc-immunoprecipitated samples at tO revealed a faint band 
in PML-/- MEFs that was absent in the wt counterpart, suggesting that some residual 
Myc activity may escape GO block.
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Fig.3.14. Analysis of Myc binding to target prom oters by chrom atin  
immunoprécipitation (ChIP). Wt and PML-/- MEFs were synchronized by serum 
starvation. DNA-protein cross-linking and cell harvesting was performed before (tO) 
and 6, 12, 16, and 20 hours after induction of cell cycle re-entry by serum addition. An 
aliquot of extract for each time point was set apart to quantify total DNA. (a): 
im m unoprécipitation with anti-M yc N-262 antibody; (-): no antibody. 
Immunoprecipitated samples were subjected to reversal of cross-linking and DNA 
purification, and the enrichment in the promoter region of Myc target genes was 
assayed by performing PCR analysis with specific primers (see Materials and 
Methods). Both genes target for up-regulation (up) and down-regulation (down) were 
analysed (see Table 1).
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3.6.2- Analysis of Myc target genes by Real-Time PCR
In parallel with the ChIP analysis, I monitored the expression profile of 40 
genes (TableI), including all of the genes analysed by ChIP, and others for which the 
direct influence of Myc has already been proven, by performing quantitative PCR 
analysis at the same time points. Significantly, in the G I phase (t6 and tI2), which 
coincides with the peak of c-myc expression and Myc protein activity, many of the 
target genes, both activated and repressed, showed an increased expression in PML-/- 
MEFs compared to wt.
Table I summarizes the differences observed in the gene expression profile 
between the two cell types at the selected time points. For all of the genes, the 
expression differences between the two cell types at each time point were analysed by 
performing the paired Student’s r-test. This test focuses on the difference between 
paired data, and reports the probability that the mean difference is consistent with 
zero. This statistical function proved suitable for my study, as I needed to pair the 
expression data obtained from wt and PML-/- MEFs of every single experiment, when 
evaluating the consistency of the mean differences.
As shown, 21 out of 40 genes analysed display a statistically significant 
increase of expression in PML-/- G I cells (Student’s r<0.05), and many of the 
remaining 19 genes show this same trend (see Fig.3.I5 and 3.16). In the table, genes 
are divided into subgroups corresponding either to significantly increased expression 
in wt or PML-/- cells, or to no increase in the G I phase (t6 and tI2). Fig.3.I5 shows 
the altered expression profiles of TMP and Pdgfr, two genes that are reported targets 
for up- and down-regulation by Myc, respectively. Of the genes analysed, p2I is the
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only one that is more expressed in wt cells. p21 is also a direct target of p53, which 
shows defective activity in PML-/- MEFs (Fogal et al., 2000; Guo et al., 2000). It is 
possible that p21 gene misexpression is determined by an epistatic effect of p53. The 
expression profile of the other genes analysed is reported in Fig.3.I6.
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gene name gene fcodtntt regulation ChIP’ Real Tiiue^
to t6 tl2 tl6 t20
Cdkiila(fÊl) wcMn-dependent kinase inMtdta 1 A(P21) down 4. wt wt wt wt wt
Teat teliunera: e r e\f eis e trans cnpæe doum* + wt wt n.d n.d nd
Ai3m adrenconeduDin dovrn + wt n.d n.d V-
C dlaû a pi 6, inhibits CDK4 doufn + nd. n.d -A n d
C dbiilb(p27) cy din-dependent kinase inhibitor 1B (92,1) iloD/n + nd. -/- -A -A V-
Eca40 brat died drain aminotr ans faas e 2 dotvn* + -i- -/- n.d n.d V-
Ftli tdiitinheaiy chain down + V- n.d V -
I s è f i ê
IFN ilepetidentpcsitive acting transcription factor 3 
gamma down* * n.d n.d -A -A
N m N eu cnccgene down + nd. n.d -A -A n d
Pdgfr platelet derived groD/th factor recept a', beta pd^peptide down * nd. n.d -/- n.d
Cav-1 cavedin down + wt n.d n d n.d n d
C cndl cydinDl dottrn + nd. n d n.d n.d n d
C dkn2b pi 5, inhitits C DK4 down + nd. n.d n.d n.d nd
Gai(W5 gadd45 dpha dioü/n + nd. n.d n.d -A - i -
EiGa eukaryotic traud ati cn Mtiatian factor 2A up + mi. wt n.d n d
Cdbi!.5a ceU division tycle25A up + V- n d -A n.d n d
Cdk4 cychn- dependent kinase 4 up + n.d n.d V-
Cull cuUin 1 up ? nd. n.d n.d nd
EiG a eulcar^Ptic trarsl ati cn initiation factor 2A up + nd. -A wt n.d nd
1.12 inlribitor of DN A binding 2 up n.p V- -A -A n.d -i-
2310CeiG]lRik
LDH-A
(murine handogue of c-Myc target TPOl) 
lactate dehydrogenase-A
up
up
n.p -t-
V- n.d -A
-A
n.d
n d
nd
LOC3811D1 mouse homdogue of RCL c-Myc resporeive gate up + V- -A n.d n.d
Tlitsl thrcmboGpondin-1 i p * + nd. n.d -A n.d V-
Tkl thymidine kinase 1 up n.p nd. n.d -A V-
TT4P pdthdial membrane protein 1 up + wt -A n.d n.d n d
Trp53 trareformation related protein 53 pfi3 up + nd. n.d -A wt wt
YtKl Y boK protein 1 up n.p nd. -A -A -A -Î-
B23 nucleoptiosmin 1 up + nd. n.d n.d n.d n d
Bax BCL2-associated X potedn up + nd. n.d n.d n.d n d
BN51T RNA pd}Tnarase 111 subunit up + nd. n.d n.d n.d n d
Cad carbemoyl-phosfirate synthetase 2 aspartate transcarbam i^ase, and dihydrcorotase up * nd. n.d n.d n.d n d
C cnbl cydinBl up + nd. n.d n.d n.d n d
C cnd2 cydin D2 up + nd. n.d n.d n.d n d
D dxlS DEAD (Asp-Glu-Ala-Asp) bcK polypeptide 18 up + nd. n.d n.d wt n d
Eca39 branched drain aminotr are feras e 1 up + nd. n.d n.d n.d n d
Eif4e eukaryoti c translation initiation factor 4E up + nd. n.d n.d n.d n d
Hsfl/O.l heat shock protan TOkDal down + n.p np n.p n.p n p
Nucl nucledin up + nd. n.d n.d n.d n d
0  dc ornithine decarbojylase structure up + nd. n.d n.d n.d nd
Puna protlTjunosin alpha up + nd. n.d n.d n.d nd
Table 1. Myc target gene analysis by ChIP and Real Time PCR.
a: + = positive result; ?= unclear; n.p.= not performed
b: wt= genes more expressed in wt cells; -/-= genes more expressed in PML-/- 
cells; = G1 phase; n.d.= no statistical difference; *= the asterisk indicates 
expression profiles opposite to what reported in literature.
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3.6.3-Analysis of the expression data
Fig.3.17 summarizes the expression data, and shows the number of genes that 
are differentially expressed in the two cell types at each cell phase. The diagrams 
illustrate the distribution of genes up- or down-regulated by Myc, separately or 
together. At tO, while cells are kept in the GO phase, most genes do not show 
differences in the expression levels between the two cell types. At t6+ tl2 , 
corresponding to the G1 phase, there is a strong increase in the number of genes, both 
activated and repressed by Myc, which are more expressed in PML-/- cells. This 
number decreases as cells enter the S phase (tl6), notwithstanding the difference 
between the outlines of the two gene groups. In fact, the expression levels of the up- 
regulated genes return to become comparable between the two cell types as soon as 
cells exit the G1 phase. In contrast, the augmented expression in PML-/- cells shown 
by down-regulated genes during G1 is mostly retained toward the S phase, indicating a 
difference of sensitivity between the mechanisms that regulate transcription in the two 
gene subpopulations.
The results obtained by ChIP and Real-Time PCR, together with the co­
localization and interaction data, strongly indicate a direct involvement of PML in 
Myc-mediated transcriptional activity.
The observation that the two oppositely regulated gene categories share the 
same kind of alteration in their expression profile after PML withdrawal suggests an 
epi static role of PML on Myc activity.
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Fig.3.15. Expression profile of Myc ta rge t genes by Real-Tim e PC R  (see 
fig.3.9). Each value is the mean of four independent experiments, and the 
differences were validated by Student’s t test (t<0.05). x-axis: time points; y- 
axis: fold expression; wt MEFs: H ;  PML-/- MEFs:
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Fig.3.17. Comparative analysis of gene expression levels in wt and PML -/- cells 
throughout cell cycle. Genes are divided in groups that show increased expression in 
MEFs wt (grey), PML-/- (black), or that show no difference (white), and compared in 
the GO (tO), in the early and middle G1 (t6-Ftl2), and in the late G 1/early S phase (tl6). 
The three diagrams display the result of the comparative analysis of the three gene 
groups in up-regulated, down-regulated or total genes.
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3.7-PML is a Myc target gene
As shown in Fig.3.10, c-myc and PML gene expression profiles show opposite 
trends throughout the cell cycle. PML is highly expressed in GO, where c-myc 
displays a basal level of expression; during the early G1 phase, c-myc expression is 
strongly induced, whereas PML expression curve drops dramatically, and is re­
induced by late G l. I hypothesized that PML might be a Myc target gene, and that 
Myc might participate to PML gene repression in G l. Using the rVISTA analysis, 
(Loots et al., 2002), I compared the mouse and human PML promoter regions, and we 
identified a highly conserved promoter region, spanning lOObp 5 ’ of the Inr sequence. 
Particularly, this sequence contains several Spl putative binding sites (Fig.3.18A). As 
Myc can inhibit gene expression by physical interaction with both the Inr-complex and 
Spl (Gartel and Shchors, 2003), I checked whether Myc binds to the PML promoter. 
Chip was performed using NIH-3T3 cells starved by 48-hour serum withdrawal, and 
harvested before (tO) or 3 hours after serum was re-added to the culture medium (t3), 
in order to obtain two cell populations in GO and in the early G l phase, respectively. 
Chip successfulness was confirmed by performing PCR using nucleolin-specific 
primer pairs (Fig.3.18B). PCR analysis was performed using two different primer 
pairs, one of which including the conserved sequence and the Inr, and the other 
spanning -500 to -300bp 5’ of the Inr. As shown in Fig.3.18, a strong enrichment of 
the Inr-containing sequence was observed. As the chromatin sonication step preceding 
immunoprécipitation produced 300-2000bp fragments, a lower but consistent 
enrichment of the adjacent region was also detected. Myc binding to the PML
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promoter strongly indicates that Myc is directly involved in PML transcriptional 
control.
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Fig.3.18. PM L is a  Myc target. (A) Schematic representation of the comparison 
between the murine and the human PML promoter. The pink-coloured area 
indicates the most conserved region between the two species. PML.l and PML.2 
indicates the regions amplified by PCR following ChIP assay. (B) ChIP performed 
on synchronized NIH-3T3 murine fibroblasts, a = anti-Myc antibody; - = no 
antibodv.
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CHAPTER 4; Discussion
In metazoans, cell growth, survival and commitment are major regulatory 
functions that need to undergo severe combinatorial regulation to keep every cell 
system in the designed equilibrium. Cells are sensitive to a variety of extra-cellular 
stimuli that trigger specific intra cellular signalling pathways and that play crucial 
roles in cell fate maintenance. The integration of these diverse signals by proteins that 
regulate cell proliferation, differentiation, and apoptosis, ultimately determines the 
response of individual cells. Mutations that perturb this system often predispose or 
determine genetic diseases and cancer. Myc and PML are two essential integrators of 
extracellular stimuli that seem to play antagonistic and overlapping roles in cellular 
response. The data I have presented show for the first time that Myc and PML 
physically interact and that Myc partially localizes within the NB. Moreover, these 
results indicate that this interaction seems to have functional consequences on Myc 
activity, as the absence of PML alters the expression of numerous Myc target genes.
4.1-PML influences the expression of Myc target genes
In PML-/- MEFs, Myc target genes display a general up-regulated expression 
during the G I phase, when Myc reaches its peak of transcriptional activity, suggesting 
that Myc function is somehow altered. The genes selected for this study belong to 
diverse cell functions, such as growth, proliferation, and survival. I could not associate 
the observed differences of expression to any of these subgroups, further suggesting 
that a general deregulation of Myc-mediated transcriptional activity occurs.
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The proto-oncogene c-myc executes multiple activities mostly through the 
transcriptional regulation of target genes. Myc can activate genes through multiple 
regulatory events both at the level of transcriptional initiation and elongation 
(Bouchard et al., 2001; Cheng et al., 1999; Eberhardy and Farnham, 2001; Frank et al., 
2001; Xu et al., 2001). By contrast, Myc seems to repress transcription by interfering 
with the transcriptional machinery or with the enhancers that are required for the 
activation of the target genes (Feng et al., 2002; Gartel et al., 2001; Izumi et al., 2001; 
S taller et al., 2001; Watanabe et al., 2002). As both activated and repressed Myc target 
genes share the same tendency in PML-/- cells, PML probably does not influence the 
two distinct pathways; rather, it might affect some upstream regulation of Myc 
activity. More than 50% of the genes show a statistically significant increase of 
expression in PML-/- G l cells compared to wt. Likewise, many of the remaining 
genes reveal the same trend. In some specific cases, such as for p21 expression, the 
genes selected might also be controlled by other transcription pathways, the function 
of which would be possibly affected by the lack of PML as well. It is also possible that 
the result obtained in murine fibroblast may vary in different tissues, depending on the 
two proteins abundance or on the involvement of additional specific partners.
4.2-PML does not affect Myc binding to chromatin targets
The effect of PML on Myc transcriptional activity does not seem due to 
interference with Myc DNA-binding properties. The PCR reactions that I performed 
on Chip samples are semi-quantitative, as I could clearly observe the enrichment of
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Myc binding to the regulatory regions of the target genes throughout the Gl phase. 
My results indicate that Myc binding to DNA is independent of the presence of PML.
4.3-Myc involvement in PML transcription
The discovery that PML is a Myc target gene suggests that the two genes 
might undergo reciprocal transcriptional regulation. PML has been recently involved 
in the P-catenin and plakoglobin transcription pathways, which regulate the 
transcription of proliferation-related genes, including c-myc (Shtutman et al., 2002). 
Moreover, PML-RARa fusion protein up-regulates the expression of the c-myc gene 
(Muller-Tidow et al., 2004). It would be interesting to verify this hypothesis within 
pathways that require a proper regulation of both genes, as for example the interferon 
(IFN) pathway. In fact, as already mentioned, PML is upregulated by interferons 
(Heuser et al., 1998); this upregulation correlates with IFN antiviral and 
antiproliferative effects. Consistent with this hypothesis, NB disruption is a 
prerequisite for viral infection (Ruggero et al., 2000; Turelli et al., 2001). Conversely, 
c-myc shares many target genes with IFN-y and c-myc overexpression correlates with 
a global deregulation of multiple IFN-response genes (Nesbit et al., 2000), possibly by 
positive or negative interaction with several INF-related transcription factors, such as 
Spl.
4.4-Trisomy of the c-myc locus is frequently associated to APL
As known, Myc over-expression is a marker of poor prognosis for several types 
of cancers (Pelengaris et al., 2002). NB are strongly involved in tumour suppression
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(Salomon! and Pandolfi, 2002), and PML localization to the NB is a prerequisite for 
the formation and the maintenance of their macromolecular structure (Ishov et al., 
1999; Zhong et al., 2000). In APL blasts, the PM L/RARa protein targets and 
délocalisés PML, causing the destruction of the NB into micro-speckled structures. 
Abrogation of the NB structure might lead to the de-regulation of Myc activity and 
predispose to cellular transformation. Intriguingly, 15-40% of patients with APL and 
t(15;17) have complete or partial trisomy of chromosome 8 as secondary defect, and 
the smallest region of gain corresponds to bands 8q23-24, where c-myc gene is 
mapped (Le Beau et al., 2002; Le Beau et al., 2003; Zimonjic et al., 2000). As well, 
PML/RARa transgenic mice develop recurring chromosomal alteration in leukemic 
cells, the majority of which associates with trisomy of chromosome 15. Murine c-myc 
maps on chromosome 15D2-3, and these bands are frequently associated to mice 
leukaemias and lymphomas. These data suggest that Myc tumorigenic pathway might 
be preferentially selected following NB disruption, which would further account for 
the requirement of intact NB for the surveillance of Myc activity.
4.5-PML directly influences Myc transcriptional activity
Transactivation assays further suggest that PML directly influences Myc- 
mediated transcription. However, the increased transcriptional activity of Myc when 
co-expressed with PML is in contrast with the results obtained in vivo, as Myc target 
genes are upregulated when PML is absent. This divergency is probably due to the 
over-expression of the two proteins, as Myc and PML expression levels are crucially 
related to their transcriptional role (Eisenman, 2001; Salomoni and Pandolfi, 2002).
88
As in this assay the balance between the two proteins is lost, the transcriptional assay 
only indicates that a cross-talk between the two proteins exists, whereas the absolute 
transcriptional result is not informative.
4.6-Does PML play a role in Myc post-translational modification?
The finding that Myc is recruited in the NB further enforces the idea that the 
PML bodies are key co-factors in modulating cell transcriptional activity, and opens 
questions concerning the mechanism by which PML influences Myc transcriptional 
activity.
4.6.1-Myc function is regulated post-translationally
Myc protein is subjected to several post-translational m odifications, 
particularly phosphorylation, glycosylation, ubiquitination and most recently 
observed, acétylation (Kamemura et al., 2002; Salghetti et al., 1999; Sears et al., 2000; 
Vervoorts et al., 2003). These modifications play diverse roles on protein fate and 
function. In fact, glycosylation antagonizes phosphorylation of Threonin 58, which is 
strictly related to Myc degradation and is a well-known mutation hotspot, which 
renders cells tumour prone (Gregory and Hann, 2000). Also, ubiquitination has 
recently emerged as a wide mechanism that regulates the functional activation of 
transcription factors (Salghetti et al., 2001). Besides targeting Myc degradation 
(Salghetti et al., 1999), ubiquitination enhances Myc transcriptional activity via 
recruitment of proteasome subunits, which have been found together with Myc on the
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promoter of the gene encoding for cyclin D2 (Kim et al., 2003; von der Lehr et al., 
2003). It was recently proposed that ubiquitination of Myc protein might compete with 
acétylation by CBP (Vervoorts et al., 2003). Interestingly, other than recruiting CBP at 
the NB, PML interacts with the proteasome as well (Lallemand-Breitenbach et al., 
2001), even if the functional significance of this interaction is still obscure.
4.6.2-Post-translational modiflcations at the NB
In the localization experiments, I observed that only a small amount of Myc 
localizes to the NB. This is consistent with the data reported for other transcription 
factors that functionally interact with PML (Fang et al., 2002; Fogal et al., 2000; Wu 
et al., 2002). It is possible to hypothesize that the NB regulate just a small sub-pool of 
Myc protein, or that the turnover of the interaction is extremely rapid. As known, NB 
are sites of regulation of transcription factor post-translational modifications, such as 
phosphorylation, acétylation and sumoylation (Best et al., 2002; Moller et al., 2003; 
Pearson et al., 2000), and are engaged in gene expression via preferential recruitment 
of transcription co-factors such as histone acetyltransferases (HATs) like CBP and 
p300 (Doucas et al., 1999; LaMorte et al., 1998), or histone deacetylases (HDAC) and 
co-repressors ((Khan et al., 2001; Langley et al., 2002; Wu et al., 2001), represented 
in Fig.4.1).
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4.6.3-Inhibition of Myc degradation pathway induces increased  
interaction with PML
As Myc and PML are both engaged by the proteasome, we investigated if Myc 
recruitment to the NB could be affected by blocking the proteasome degradation 
pathway. Immunolocalization and immunoprécipitation performed in cells treated with 
proteasome inhibitor show that the pool of Myc protein co-localizing and interacting 
with PML dramatically increases. This enrichment suggests that the amount of Myc 
that is recovered at the NB strongly depends on its post-translational turnover. I 
observed that a small amount of Myc localizes at the NB, suggesting transient and 
dynamic interaction. This is consistent with the data reported for other transcription 
factors that interact with PML, as well as for other PML interactors, such as CBP 
(Borden, 2002). Myc and PML belong to a subset of proteins that translocate to the 
nucleoli when overexpressed or by inhibition of the proteasome-mediated degradation 
(Arabi et al., 2003) (Mattsson et al., 2001). In HeLa cells, PML takes several hours to 
localize in the nucleolus following proteasome inhibition; however, when I 
overexpress Myc, strong co-localization of the two proteins with the proteasome at the 
nucleolus and in Myc nuclear inclusions is detected after 3 hours. As Myc localization 
to the nucleoli is a dynamic and reversible process that engages the proteasome, I 
hypothesize that Myc accumulation induced by overexpression and proteasome 
inhibition also stabilizes the dynamic interaction with PML. These data further 
suggest that the interaction between Myc and PML may depend on Myc post- 
translational status.
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4.6.4-Proposed model
Myc recruitment in the NB and physical interaction with PML opens questions 
concerning the mechanism by which PML influences Myc transcriptional activity. 
Therefore, we hypothesize that PML might recruit Myc to the NB and influence its 
activity, modulating the status of Myc protein (compare figure Fig4.1a and b). Due to 
the multiple regulatory mechanisms it takes part in, we propose that Myc selectively 
binds distinct partners depending on its post-translational status. If PML is lacking, 
this balance is perturbed, and Myc protein modifications might render Myc more 
efficient as a transcriptional activator of the up-regulated genes than as a mediator of 
repression of the down-regulated ones.
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Fig.4.1. Schematic representation of the PML and Myc pathway, before (a), and after (b) 
this study was performed. The transient recruitment of Myc to the NB could modify Myc 
post-translational status and contribute to address Myc toward its biological functions.
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